HGCSG

実績一覧

RESULT

HGSCGの業績集

Achivements

総説・論文など

国際学会

国内発表

2023年

Harada K, Yamamura T, Muto O, Nakamura M, Sogabe S, Sawada K, Nakano S, Yagisawa M, Muranaka T, Dazai M, Tateyama M, Kobayashi Y, Kato S, Hatanaka K, Kawamoto Y, Yuki S, Sakata Y, Sakamoto N, Komatsu Y

Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101)

Journal of Clinical Medicine 2023 Vol 12 Issue 4, 1596

https://doi.org/10.3390/jcm12041596

2022年

Nakano S, Kawamoto Y, Yuki S, Harada K, Miyagishima T, Sogabe S, Dazai M, Sato A, Ishiguro A, Nakamura M, Kajiura S, Takahashi Y, Tateyama M, Hatanaka K, Tsuji Y, Sasaki T, Shindo Y, Kobayashi T, Yokota I, Sakamoto N, Sakata Y, Komatsu Y.

Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer

BMJ Open 2022 Vol. 12 Issue 5 Pages e048833

https://bmjopen.bmj.com/content/12/5/e048833

Kawamoto Y, Yuki S, Sawada K, Nakamura M, Muto O, Sogabe S, Shindo Y, Ishiguro A, Sato A, Tsuji Y, Dazai M, Okuda H, Meguro T, Harada K, Sekiguchi M, Okada K, Ito M. Y, Sakata Y, Sakamoto N, Komatsu Y.

Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603

Oncologist 2022 Vol. 27 Issue 8 Pages e642-e649

https://academic.oup.com/oncolo/advance-article/doi/10.1093/oncolo/oyac086/6586834

Kawamoto Y, Yuki S, Meguro T, Hatanaka K, Uebayashi M, Nakamura M, Okuda H, Iwanaga I, Kato T, Nakano S, Sato A, Harada K, Oba K, Sakata Y, Sakamoto N, Komatsu Y.

Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)

Oncologist 2022 Vol. 27 Issue 5 Pages 340-e374

https://academic.oup.com/oncolo/article/27/5/340/6550607

Ito K, Yuki S, Nakatsumi H, Kawamoto Y, Harada K, Nakano S, Saito R, Ando T, Sawada K, Yagisawa M, Ishiguro A, Dazai M, Iwanaga I, Hatanaka K, Sato A, Matsumoto R, Shindo Y, Tateyama M, Muranaka T, Katagiri M, Yokota I, Sakata Y, Sakamoto N, Komatsu Y.

Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer

Support Care Cancer 2022 Vol. 30 Issue 6 Pages 5351-5359

https://link.springer.com/article/10.1007/s00520-022-06936-4k

Nakatsumi H, Komatsu Y, Muranaka T, Yuki S, Kawamoto Y, Harada K, Dazai M, Tateyama M, Sasaki Y, Miyagishima T, Tsuji Y, Katagiri M, Nakamura M, Sogabe S, Hatanaka K, Meguro T, Kobayashi T, Ishiguro A, Muto O, Shindo Y, Kotaka M, Ando T, Takagi R, Sakamoto N, Sakata Y.

Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies

Front Oncol 2022 Vol. 12 Pages 939425

https://doi.org/10.3389/fonc.2022.939425

Nakamura M, Ishiguro A, Dazai M, Kawamoto Y, Yuki S, Sogabe S, Hosokawa A, Sawada K, Muto O, Izawa N, Nakashima K, Horie Y, Yagisawa M, Kajiura S, Ando T, Mitsuhashi Y, Sunakawa Y, Kikuchi Y, Komatsu Y.

Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study

BMC Cancer 2022 Vol. 22 Issue 1 Pages 1322

https://bmccancer.biomedcentral.com/articles/10.1186/s12885-022-10403-y

2021年

Kawamoto Y, Nakatsumi H, Harada K, Muranaka T, Ishiguro A, Kobayashi Y, Hayashi H, Yuki S, Sawada K, Yagisawa M, Nakano S, Sakamoto N, Komatsu Y.

A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403)

Oncologist 2021 Vol. 26 Issue 10 Pages e1675-e1682

https://academic.oup.com/oncolo/article/26/10/e1675/6513518

2020年

Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Kobayashi K, Esaki T, Nakashima Y, Kawanaka H, Emi Y, Komatsu Y, Shimokawa M, Makiyama A, Saeki H, Oki E, Baba H, Mori M.

Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B.

Cancer Chemother Pharmacol. 2020 Jan;85(1):217-223.

https://link.springer.com/article/10.1007%2Fs00280-019-03991-3

2018年

Yamada Y, Denda T, Gamoh M, Iwanaga I, Yuki S, Shimodaira H, Nakamura M, Yamaguchi T, Ohori H, Kobayashi K, Tsuda M, Kobayashi Y, Miyamoto Y, Kotake M, Shimada K, Sato A, Morita S, Takahashi S, Komatsu Y, Ishioka C.

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.

Ann Oncol. 2018 Mar 1;29(3):624-631.

https://www.sciencedirect.com/science/article/pii/S0923753419355097?via%3Dihub

Tanioka H, Miyamoto Y, Tsuji A, Asayama M, Shiraishi T, Yuki S, Kotaka M, Makiyama A, Shimokawa M, Shimose T, Masuda S, Yamaguchi T, Komatsu Y, Saeki H, Emi Y, Baba H, Oki E, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).

Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402).

Oncology. 2018;94(5):289-296.

https://www.karger.com/Article/FullText/486624

2017年

Nakamura M, Ishiguro A, Muranaka T, Fukushima H, Yuki S, Ono K, Murai T, Matsuda C, Oba A, Itaya K, Sone T, Yagisawa M, Koike Y, Endo A, Tsukuda Y, Ono Y, Kudo T, Nagasaka A, Nishikawa S, Komatsu Y.

A Prospective Observational Study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO-01).

Oncologist. 2017 May;22(5):592-600.

https://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2016-0308

Kawamoto Y, Komatsu Y, Yuki S, Sawada K, Muranaka T, Harada K, Nakatsumi H, Fukushima H, Ishiguro A, Dazai M, Hatanaka K, Nakamura M, Iwanaga I, Uebayashi M, Sogabe S, Kobayashi Y, Miyagishima T, Ono K, Sakamoto N, Sakata Y.

Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer. [Protocol paper]

BMC Cancer. 2017 Dec 8;17(1):837.

https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3850-z

Muranaka T, Komatsu Y, Yagisawa M, Sawada K, Harada K, Kawamoto Y, Nakatsumi H, Yuki S, Ono K, Kawahata S, Kobayashi Y, Sogabe S, Miyagishima T, Hatanaka K, Sasaki T, Dazai M, Iwanaga I, Ishiguro A, Nakamura M, Sakamoto N, Sakata Y.

Feasibility Study of Bolus 5-Fluorouracil+L-Leucovorin as Salvage Line Chemotherapy for Oral Fluorouracil-Resistant Unresectable Gastric Cancer: Hokkaido Gastrointestinal Cancer Study Group Study HGCSG1502. [Protocol paper]

J Clin Trials. 7(6), 2017

https://www.longdom.org/open-access/feasibility-study-of-bolus-5fluorouracillleucovorin-as-salvage-linechemotherapy-for-oral-fluorouracilresistant-unresectable-gastri-2167-0870-1000337.pdf

2015年

Yasui H, Muro K, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Esaki T, Tokunaga S, Kuwano H, Boku N, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K.

A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study.

J Cancer Res Clin Oncol. 2015 Jan;141(1):153-60.

https://link.springer.com/article/10.1007%2Fs00432-014-1783-3

Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I, Uebayashi M, Okuda H, Kusumi T, Miyagishima T, Sogabe S, Tateyama M, Hatanaka K, Tsuji Y, Nakamura M, Konno J, Yamamoto F, Onodera M, Iwai K, Sakata Y, Abe R, Oba K, Sakamoto N.

Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP.

Future Oncol. 2015;11(4):617-27.

https://www.futuremedicine.com/doi/10.2217/fon.14.251?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed

Komatsu Y, Ishioka C, Shimada K, Yamada Y, Gamoh M, Sato A, Yamaguchi T, Yuki S, Morita S, Takahashi S, Goto R, Kurihara M.

Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. [Protocol paper]

BMC Cancer. 2015 Sep 9;15:626.

https://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1630-1

2013年

2013年1. Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.Shitara K, Yuki S, Yamazaki K, Naito Y, Fukushima H, Komatsu Y, Yasui H, Takano T, Muro K.J Cancer Res Clin Oncol. 2013 Apr;139(4):595-603.

当院を含む3つの研究機関で、大腸がんの2nd lineでイリノテカンベースの化学療法を受けた193人の患者のデータを纏めたものです。この領域は、他施設との共同戦線をひいて、協力して新しいデータを出して行かねばなりません。レトロではありますが、この手のデータも、今後は当グループ主導でも出して行かねばなりません。（小松）

2.Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.Yamaguchi K, Sawaki A, Doi T, Satoh T, Yamada Y, Omuro Y, Nishina T, Boku N, Chin K, Hamamoto Y, Takiuchi H, Komatsu Y, Saji S, Koizumi W, Miyata Y, Sato A, Baba E, Tamura T, Abe T, Ohtsu A.Gastric Cancer. 2013 Apr;16(2):175-82.

化療Ｇは、積極的に世界に目を向け、Global Trialに参加していますが、その中でAVAGAST study、TOGA studyというMega trialの中の、日本人データを解析することを、Globalから許され、その結果をまとめたものです。化療Ｇ皆の努力の賜ですが、今後も同様のGlobal Trialに参加し、世界の標準的化学療法作りに、協力・参加して行かねばなりません。（小松）

3．Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients.Kanda T, Nishida T, Wada N, Kobayashi O, Yamamoto M, Sawaki A, Boku N, Koseki M, Doi T, Toh Y, Kakeji Y, Sugiyama T, Komatsu Y, Kikuchi S, Ogoshi K, Katai H, Miyachi K, Hirota S, Ohtsu A.Int J Clin Oncol. 2013 Feb;18(1):38-45.

１０万人に１～２人という非常に希有な腫瘍で有るＧＩＳＴの中でも、高悪性度群の切除後に対するイマチニブ補助化療の治験結果を、新潟の神田先生がauthorで纏めたものです。これが唯一の本邦における前向きのＥＢＭであり、それに参加出来たことは大変嬉しい限りです。これに登録した、3人の私の患者さんは、未だに無再発でお元気に外来通院されています。最先端治験に参画し、その本邦のデータ作りに直接関わり、また、その実感を直接得られ続けるというのは、大変感慨深いものです。（小松）

Satoh T, Yasui H, Muro K, Komatsu Y, Sameshima S, Yamaguchi K, Sugihara K Pharmacokinetic assessment of irinotecan, SN-38, and SN-38-glucuronide: a substudy of the FIRIS study. Anticancer Res. 2013 Sep;33(9):3845-53. https://ar.iiarjournals.org/content/33/9/3845.long

2012年

Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. Komatsu Y, Yuki S, Sogabe S, Fukushima H, Nakatsumi H, Kobayashi Y, Iwanaga I, Nakamura M, Hatanaka K, Miyagishima T, Kudo M, Munakata M, Meguro T, Tateyama M, Sakata Y. Acta Oncol. 2012 Sep;51(7):867-72

Optimal Dose Period for Indisetron Tablets for Preventing Chemotherapy-Induced Nausea and Vomiting with Modified FOLFOX6: A Randomized Pilot Study. Nakatsumi H, Komatsu Y, Yuki S, Sogabe S, Tateyama M, Muto S, Kudo M, Kato K, Miyagishima T, Uebayashi M, Meguro T, Oba K, Asaka M. Chemotherapy. 2013 Jan 29;58(6):439-444

2012年1.TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial.Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, Tsuji Y, Moriwaki T, Esaki T, Hamada C, Tanase T, Ohtsu A.Lancet Oncol. 2012 Oct;13(10):993-1001.

大腸がんの化学療法薬と言えば、従来は世界で開発され、他国で使用可能となっても、本邦では使用出来ず、数年のdrug lagの間、指をくわえて見ているしかなかった残念な時代が長く続きました。ところが、このTAS102は、日本で開発され、日本での臨床試験が成功し、日本発のGlobal phase III studyへと進む事ができた貴重な薬剤で有り、臨床研究です。化療Ｇの実施、参加する臨床研究が、世界で通用するためには、高い臨床能力と相当数の症例数が必要となるため、単施設ではとても無理で有り、その中でも相当な努力がないと、co-authorになることもできません。今回の結果は我が化療Ｇの皆の努力と、本邦を代表する、他の施設との連携により、臨床腫瘍学では最高ランクのIFを誇るLancet Oncolにアクセプトされました。改めてグループの皆に感謝します。いずれは、当Ｇで1st autorが取れる様、また、北大化療Ｇが、世界レベルの臨床パワーを維持し、Global Studyに参加し続けられる様、皆で力を合わせて行きたいと思います。（小松）

2.Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.Komatsu Y, Yuki S, Sogabe S, Fukushima H, Nakatsumi H, Kobayashi Y, Iwanaga I, Nakamura M, Hatanaka K, Miyagishima T, Kudo M, Munakata M, Meguro T, Tateyama M, Sakata Y.Acta Oncol. 2012 Sep;51(7):867-72.

大腸がんの化学療法レジメンは、その殆ど全てが外国で考案され、報告されることが通常の中、IRISレジメンは、当化療Ｇで考案し、同門の施設を中心とした、北海道消化器癌化学療法研究会（ＨＧＣＳＧ）で臨床試験を実施した結果生み出された、純和製の北海道発のオリジナルレジメンであり、2012年の最新欧州臨床腫瘍学会ガイドラインにも載り、世界の標準治療の一つとなったものです。そのレジメンのさらなる強化レジメンであるIRIS+BVレジメンのＰＩＩが終了し結果報告したものであり、そのＯＳは世界一のデータを誇ります。本来であれば、もっと高い雑誌にアクセプトされるべきレジメンですが、Ｓ－１が本邦だけのローカル薬剤であるためやむなしと思われます。 2012年からＳ－１は欧州でも発売されたため、今後は注目度も上がることが予想されます。治験参加と違い、大学を中心とし、関わって下さった仲間の皆と名前を並べる事ができ、ことの他嬉しい論文となりました。この場を借りて、HGCSGグループの皆さんに感謝申し上げます。現在、このレジメンをWorld Standardとするべく、第III相検証試験のTRICOLORE studyが全日本規模で動いており、当Ｇもその中心的グループとして動いており、その結果を楽しみにして頂きたい。（小松）

3.Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study.Nakatsumi H, Komatsu Y, Yuki S, Sogabe S, Tateyama M, Muto S, Kudo M, Kato K, Miyagishima T, Uebayashi M, Meguro T, Oba K, Asaka M.Chemotherapy. 2012;58(6):439-44.

H4.First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.Tsuji Y, Satoh T, Tsuji A, Muro K, Yoshida M, Nishina T, Nagase M, Komatsu Y, Kato T, Miyata Y, Mizutani N, Hashigaki S, Lechuga MJ, Denda T.Cancer Sci. 2012 Aug;103(8):1502-7.

世界標準治療であるFOLFIRIとマルチキナーゼ経口ＴＫＩであるsunitinibの併用レジメン開発のための、国内のPhase II試験結果の報告です。その効果に比べて、大変副作用の強いレジメンとなり、このまま継続しても、標準的治療となる事は難しいと判断され、Phase IIIへ進むことのできなかった試験です。臨床試験とは、このようなnegative studyとなってしまう可能性もあるのですが、結果を恐れず、このような標準的治療開発治験に関わって行く事も大切であるので、今後も皆でがんばっていきたい。（小松）

Nakatsumi H, Komatsu Y, Yuki S, Sogabe S, Tateyama M, Muto S, Kudo M, Kato K, Miyagishima T, Uebayashi M, Meguro T, Oba K, Asaka M Optimal Dose Period for Indisetron Tablets for Preventing Chemotherapy-Induced Nausea and Vomiting with Modified FOLFOX6: A Randomized Pilot Study. Chemotherapy. 2012;58(6):439-44. https://www.karger.com/Article/FullText/345920

Komatsu Y, Yuki S, Sogabe S, Fukushima H, Nakatsumi H, Kobayashi Y, Iwanaga I, Nakamura M, Hatanaka K, Miyagishima T, Kudo M, Munakata M, Meguro T, Tateyama M, Sakata Y Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. Acta Oncol. 2012 Sep;51(7):867-72. https://www.tandfonline.com/doi/full/10.3109/0284186X.2012.682629

2011年

Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study. Sogabe S, Komatsu Y, Yuki S, Kusumi T, Hatanaka K, Nakamura M, Kato T, Miyagishima T, Hosokawa A, Iwanaga I, Sakata Y, Asaka M. Jpn J Clin Oncol. 2011 Apr;41(4):490-7

小松嘉人「胃がん・大腸がんを薬で抑えましょう」と言われた時単行本. 2：7-17. 2011. 8.

小松嘉人 GIST診療ハンドブック単行本. 1：9-12. 2011. 8.

曽我部進，結城敏志，高野博信，小林良充，中積宏之，佐々木尚英，川本泰之，福島拓，岩永一郎，上畠寧子，小松嘉人，浅香正博塩酸イリノテカンが原因と思われる一過性の構語障害を来した１例癌と化学療法. 38(8)：1375-1377. 2011. 8.

H. Nakatsumi，Yuki S，Kobayashi Y，Komatsu Y. Colorectal cancer chemotherapy and QOL（benefits and problems of outpatient-chemotherapy）日本臨床. 69(3)：585-588. 2011. 4.

小松嘉人，林秀幸，小林良充，川本泰之，中積宏之，結城敏志【膵癌治療の新展開；タルセバ・ジェムザール・TS-1】膵癌初承認分子標的治療薬タルセバタルセバ臨床成績，特徴，副作用および処方の実際肝・胆・膵. 64(2)：187-194. 2012. 2.

2011年1.[Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)].Sato A, Doi T, Boku N, Kato K, Komatsu Y, Yamaguchi K, Muro K, Hamamoto Y, Koizumi W, Mizunuma N, Takiuchi H.Gan To Kagaku Ryoho. 2011 Apr;38(4):561-9. Japanese. これは世界でＸＥＬＯＸ＋ＢＶが報告されるときに、本邦でもDrug lag無く、世界に遅れないために、相当の決意で実施したＪＯ19380試験の結果を纏めたものです。(小松）

Sogabe S, Komatsu Y, Yuki S, Kusumi T, Hatanaka K, Nakamura M, Kato T, Miyagishima T, Hosokawa A, Iwanaga I, Sakata Y, Asaka M Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study. Jpn J Clin Oncol. 2011 Apr;41(4):490-7. https://academic.oup.com/jjco/article/41/4/490/1863278

Komatsu Y, Yuki S, Sogabe S, Fukushima H, Iwanaga I, Kudo M, Tateyama M, Meguro T, Uebayashi M, Saga A, Sakata Y, Asaka M Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). Oncology. 2011;80(1-2):70-5. https://www.karger.com/Article/FullText/328739

Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). Komatsu Y, Yuki S, Sogabe S, Fukushima H, Iwanaga I, Kudo M, Tateyama M, Meguro T, Uebayashi M, Saga A, Sakata Y, Asaka M. Oncology. 2011;80(1-2):70-5

2010年

Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer. Komatsu Y, Yuki S, Fuse N, Kato T, Miyagishima T, Kudo M, Kunieda Y, Tateyama M, Wakahama O, Meguro T, Sakata Y, Asaka M. Adv Ther. 2010 Jul;27(7):483-92

Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies. Yuki S, Komatsu Y, Fuse N, Kato T, Miyagishima T, Kudo M, Watanabe M, Tateyama M, Kunieda Y, Wakahama O, Sakata Y, Asaka M. Clin Drug Investig. 2010;30(4):243-9

小松嘉人，小林良充，中積宏之，結城敏志各論 PIVOTAL試験国内vs国外 3-2)スーテント血管新生阻害薬のベストマネージメント薬剤．2010．

小松嘉人GIST診療ハンドブック．2010．8

結城敏志，曽我部進，小松嘉人，浅香正博特集II 消化器癌の分子標的治療治癒切除不能進行/再発結腸直腸癌におけるベバシズマブの有用性と安全性を検討するレトロスペクティブ調査(HGCSG0801)．消化器内科．51：59-68．2010．7．

結城敏志，曽我部進，小松嘉人特集変わりゆく大腸がん化学療法-FOLFOX，FOLFIRI，そして次の10年 5．分子標的治療薬-導入後，治療はどう変わったか？ 3)パニツムマブへの期待と欧米での現状．臨床腫瘍プラクティス．6：151-157．2010．5．

結城敏志，小松嘉人 C．大腸癌 15 大腸癌薬物療法における経口抗癌剤の位置づけは？(何をどのように選択すればよいのか？) EBM 癌化学療法-分子標的治療法 2011-2012．:70-74．2010．11．

結城敏志, 曽我部進, 小松嘉人, 浅香正博特集II. 消化器癌の分子標的治療治癒切除不能進行/ 再発結腸直腸癌におけるベバシズマブの有用性と安全性を検討するレトロスペクティブ調査 (HGCSG0801) 消化器内科. 51(1):59-68, 2010

Komatsu Y, Yuki S, Fuse N, Kato T, Miyagishima T, Kudo M, Kunieda Y, Tateyama M, Wakahama O, Meguro T, Sakata Y, Asaka M Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer. Adv Ther. 2010 Jul;27(7):483-92. https://link.springer.com/article/10.1007/s12325-010-0037-2

Yuki S, Komatsu Y, Fuse N, Kato T, Miyagishima T, Kudo M, Watanabe M, Tateyama M, Kunieda Y, Wakahama O, Sakata Y, Asaka M Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies. Clin Drug Investig. 2010;30(4):243-9. https://link.springer.com/article/10.2165%2F11534470-000000000-00000

Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K rinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol. 2010 Sep;11(9):853-60. https://www.sciencedirect.com/science/article/pii/S1470204510701819?via%3Dihub

2009年

小松嘉人，曽我部進，川本泰之，岩永一郎，上畠寧子，結城敏志，浅香正博【セカンドライン化学療法・分子標的治療の進歩】大腸癌のSecond-Line化学療法分子標的薬の進歩癌と化学療法． 36：721-725．2009．5．

小松嘉人，曽我部進，川本泰之，岩永一郎，上畠寧子，結城敏志，浅香正博抗がん剤を知る薬剤選択のための知識スニチニブ臨床腫瘍プラクティス．5：178-182．2009．5．③小松嘉人

コンセンサス癌治療．8：171-172．2009．8．④小松嘉人，結城敏志，曽我部進，岩永一郎，中積宏之，佐々木尚英，浅香正博

切除不能進行・再発大腸がんに対する化学療法標準治療としてのFOLFOX/FOLFIRI療法を知るMebio． 26：48-55．2009．10．

小松嘉人，中積宏之，佐々木尚英イマチニブ標準治療耐性GIST患者に対するイマチニブ増量療法の検討消化器内科．50：140-144．2010．2．

小松嘉人，岩永一郎，結城敏志，曽我部進，中積宏之，佐々木尚英分子標的治療薬スニチニブ（スーテント）Biotherapy．24：172-177．2010．3

小松嘉人分子標的薬「スニチニブ」により、長期の病態コントロールを可能とした消化管間質腫瘍癌の臨床． 55：549-553．2009．10．

曽我部進，結城敏志，高木智史，宮崎拓自，高野博信，川本泰之，岩永一郎，上畠寧子，小松嘉人，浅香正博癌性リンパ管症を伴ったS状結腸癌に対して分子標的薬を併用した治療が奏功した1例癌と化学療法． 37：535-538．2010．3．

2008年

結城敏志、小松嘉人、舘山美樹、中村路夫、浅香正博. 切除不能進行結腸直腸癌に対するイリノテカン＋S-1併用療法. 消化器科, 46(3)：291-298, 2008

小松嘉人, 岩永一郎, 浅香正博. 大腸癌化学療法に用いられる投与スケジュール 2)塩酸イリノテカンを用いた投与スケジュールと, その選択基準は. 臨床腫瘍プラクティス, 4(1)：17-23, 2008

結城敏志, 小松嘉人, 浅香正博. ECCO14より. 臨床腫瘍プラクティス, 4(1)：92-93, 2008

結城敏志, 小松嘉人, 宮城島拓人, 工藤峰生, 浅香正博胃癌-基礎・臨床研究のアップデート- IX.治療-現状・動向・評価- 各論：胃癌化学療法-現状・動向・評価- 併用療法 CPT-11との併用療法 CPT-11＋S-1 日本臨牀. 66(Suppl 5):391-394, 2008

結城敏志, 小松嘉人, 舘山美樹, 中村路夫, 浅香正博切除不能進行結腸直腸癌に対するイリノテカン＋S-1併用療法消化器科. 46(3):291-298, 2008

2007年

小松嘉人、結城敏志、浅香正博. HGCSG(北海道消化器癌化学療法研究会)での取り組みと現状. 外科治療:97(2); 188-192, 2007

小松嘉人. 日本における大腸癌補助化学療法の現況と問題点. 癌と化学療法, 34(5) : 799-807, 2007.

小松嘉人. 大腸癌薬物療法の進歩. 癌と化学療法, 34(11) : 1771-1776, 2007.

小松嘉人, 結城敏志, 浅香正博 HGCSG (北海道消化器癌化学療法研究会) での取り組みと現状外科治療. 97(2):188-192, 2007

2006年

小松嘉人, 結城敏志, 宮城島拓人, 浅香正博. 胃癌に対するCPT-11+S-1併用(IRIS)療法 - S-1 2週投薬法 -. 癌と化学療法, 33 : 75-78, 2006.

小松嘉人, 結城敏志, 舘山美樹, 工藤峰生, 浅香正博. 大腸癌に対するCPT-11+S-1併用(IRIS)療法 - S-1 2週投薬法 -. 癌と化学療法, 33 : 131-134, 2006.

小松嘉人, 結城敏志, 宮城島拓人, 浅香正博胃癌に対するCPT-11＋S-1併用 (IRIS) 療法 -S-1 2週投薬法- 癌と化学療法. 33(Suppl 1):75-78, 2006

小松嘉人, 結城敏志, 舘山美樹, 工藤峰生, 浅香正博大腸癌に対するCPT-11＋S-1併用 (IRIS) 療法 -S-1 2週投薬法- 癌と化学療法. 33(Suppl 1):131-134, 2006

2005年

Komatsu Y, Yuuki S, Fuse N, Takei M, Kato T, Miyagishima T, Kudo M, Kunieda Y, Tateyama M, Wakahama O, Meguro T, Ohizumi H, Watanabe M, Akita H, Sakata Y, Asaka M. Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302. Jpn J Clin Oncol. 2005；35(2)：88-9

結城敏志, 小松嘉人, 宮城島拓人, 若浜理, 浅香正博, 坂田優. 症例提示切除不能進行胃がんに対する塩酸イリノテカン+ティーエスワン併用療法によって著効であった2例 Hokkaido Gastrointestinal Cancer Study Group(HGCSG0303). 臨床腫瘍プラクティス, 1(1)：101-104, 2005

小松嘉人, 結城敏志. 臨床医による新薬の評価オキサリプラチン抗悪性腫瘍薬. クリニカルプラクティス, 24(11)：1192-93, 2005

小松嘉人、天野虎次、秋田弘俊【腫瘍内科日本の新しいがん診療の体制を目指して】腫瘍内科の日常診療各臓器別腫瘍内科医の診療の実際大腸癌 Modern Physician. 25：1233-1239, 2005

Komatsu Y, Yuki S, Fuse N, Takei M, Kato T, Miyagishima T, Kudo M, Kunieda Y, Tateyama M, Wakahama O, Meguro T, Ohizumi H, Watanabe M, Akita H, Sakata Y, Asaka M Phase II Study of Oral S-1 Plus Irinotecan in Patients with Advanced Colorectal Cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302. [Protocol paper] Jpn J Clin Oncol. 2005 Feb;35(2):88-9. https://academic.oup.com/jjco/article/35/2/88/1785328

結城敏志, 小松嘉人, 宮城島拓人, 若浜理, 浅香正博, 坂田優切除不能進行胃がんに対する塩酸イリノテカン＋ティーエスワンⓇ併用療法によって著効であった2例 -Hokkaido Gastrointestinal Cancer Study Group (HGCSG0303) - 臨床腫瘍プラクティス. 1(1):101-104, 2005

2024年

Atsushi Ishiguro, Hiroshi Nakatsumi, Kazuaki Harada, Satoshi Yuki, Kentaro Sawada, Susumu Sogabe, Takayuki Ando, Yusuke Sasaki, Ayumu Yoshikawa, Michio Nakamura, Masayoshi Dazai, Miki Tateyama, Osamu Muto, Masahito Kotaka, Tamotsu Sagawa, Kazuteru Hatanaka, Ryo Takagi, Yuh Sakata, Yoshito Komatsu

HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer (mCRC) refractory to anti-EGFR antibodies.

2024 ASCO Gastrointestinal Cancers Symposium. San Francisco, Jan 18 - 21, 2024

Kazuaki Harada, Shintaro Nakano, Yasuyuki Kawamoto, Kentaro Sawada, Takuto Miyagishima, Susumu Sogabe, Yoshimitsu Kobayashi, Ken Ito, Atsushi Sato, Chen Yu, Masayoshi Dazai, Satoshi Yuki, Isao Yokota, Yoshito Komatsu

HGCSG 1803: Single-arm phase II study evaluating efficacy of Oxaliplatin, Irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first line treatment.

2024 ASCO Gastrointestinal Cancers Symposium. San Francisco, Jan 18 - 21, 2024

2023年

Kentaro Sawada, Shintaro Nakano, Yasuyuki Kawamoto, Takuto Miyagishima, Susumu Sogabe, Ken Ito, Atsushi Sato, Chen Yu, Masayoshi Dazai, Kazuaki Harada, Satoshi Yuki, Isao Yokota, Yoshito Komatsu

HGCSG 1803: Single-arm phase Ⅱ study evaluating efficacy of Oxaliplatin, Irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first line treatment.

WCGIC 2023. Barcelona, Jun 28 - Jul 1, 2023

2022年

Kazuaki Harada, Takahiro Yamamura, Osamu Muto, Michio Nakamura, Susumu Sogabe, Kentaro Sawada, Shintaro Nakano, Masataka Yagisawa, Tetsuhito Muranaka, Masayoshi Dazai, Miki Tateyama, Ken Ito, Rika Saito, Yoshimitsu Kobayashi, Sosuke Kato, Takuto Miyagishima, Yasuyuki Kawamoto, Satoshi Yuki, Yuh Sakata, Naoya Sakamoto, Yoshito Komatsu

Impact of single-heterozygous UGT1A1 on the clinical outcomes of nano-liposomal irinotecan plus 5-fluorouracil/leucovorin for patients with pancreatic ductal adenocarcinoma

ESMO World Congress on Gastrointestinal Cancer 2022. Jun 29 - Jul 2, 2022

Impact of single-heterozygous UGT1A1 on the clinical outcomes of nano-liposomal irinotecan plus 5-fluorouracil/leucovorin for patients with pancreatic ductal adenocarcinoma

ESMO Asia Congress 2022. Singapore, Dec 2 - 4, 2022

Ito K, Yuki S, Nakatsumi H, Ando T, Sawada K, Yagisawa M, Ishiguro A, Dazai M, Iwanaga I, Hatanaka K, Sato A, Matsumoto R, Shindo Y, Tateyama M, Muranaka T, Katagiri M, Yokota I, Sakata Y, Sakamoto N, Komatsu Y.

HGCSG1902: Multicenter, prospective, observational study for cases with dysgeusia caused by chemotherapy for gastrointestinal cancer.

[Poster session] 2022 Gastrointestinal Cancers Symposium. WEB, Jan 20-22, 2022

2021年

Nakamura M, Ishiguro A, Dazai M, Kawamoto Y, Yuki S, Sogabe S, Hosokawa A, Sawada K, Muto O, Umemoto K, Izawa N, Nakashima K, Yagisawa M, Kajiura S, Mitsuhashi Y, Ando T, Sunakawa Y, Kikuchi Y, Yamanaka T, Komatsu Y.

The safety and efficacy of edoxaban for the cancer-associated asympromatic venous thromboembolism in Japanese gastrointestinal cancerpatients receiving chemotherapy. (ExCAVE study).

[Poster session] ESMO Congress 2021. WEB, Sep 16-21, 2021

Nakano S, Harada K, Yuki S, Saito R, Ito K, Yamamura T, Kawamoto Y, Hatanaka K, Yagisawa M, Sawada K, Dazai M, Tsuji Y, Yokota I, Sakamoto N, Sakata Y, Komatsu Y.

HGCSG2002: A prospective multicenter observational biomarker study for nivolumab treatment in advanced esophageal cancer.

[Poster session; Trials in progress] ESMO Congress 2021. WEB, Sep 16-21, 2021

Ito K, Yuki S, Nakano S, Yagisawa M, Sawada K, Ishiguro A, Muto O, Hatanaka K, Okuda H, Sato A, Sasaki Y, Nakamura M, Sasaki T, Kobayashi T, Dazai M, Nakatsumi H, Ueda A, Tateyama M, Sogabe S, Matsumoto R, Sakata Y, Komatsu Y.

HGCSG1901: A Retrospective Cohort Study Evaluating the Safety and Efficacy of S-1 and Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer: Analysis of first line treatment.

[Poster session] ESMO World Congress on Gastrointestinal Cancer 2021. WEB, Jun 30-Jul 3, 2021

Kaneko S, Ito K, Yuki S, Harada K, Yagisawa M, Sawada K, Ishiguro A, Muto O, Hatanaka K, Okuda H, Sato A, Sasaki Y, Nakamura M, Sasaki T, Tsuji Y, Ando T, Kato K, Wakabayashi T, Kotaka M, Takahashi Y, Sakata Y, Komatsu Y.

HGCSG1901: A Retrospective Cohort Study Evaluating the Safety and Efficacy of S-1 and Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer: Analysis of second line treatment.

[Poster session] ESMO World Congress on Gastrointestinal Cancer 2021. WEB, Jun 30-Jul 3, 2021

Yoshikawa A, Ito K, Yuki S, Kawamoto Y, Saito R, Yamamura T, Yagisawa M, Ishiguro A, Muto O, Hatanaka K, Okuda H, Sato A, Sasaki Y, Nakamura N, Sasaki T, Kobayashi T, Dazai M, Nakatsumi H, Ueda A, Sakata Y, Komatsu Y.

HGCSG1901: A Retrospective Cohort Study Evaluating the Safety and Efficacy of S-1 and Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer: Analysis of second line treatment after Anti-EGFR antibody.

[Poster session] ESMO World Congress on Gastrointestinal Cancer 2021. WEB, Jun 30-Jul 3, 2021

Nakamura M, Kawamoto Y, Yuki S, Sawada K, Muto O, Sogabe S, Shindo Y, Ishiguro A, Sato A, Tsuji Y, Dazai M, Okuda H, Sasaki T, Harada K, Nakatsumi H, Iuchi K, Ito Y, Sakata Y, Sakamoto N, Komatsu Y.

Update results of HGCSG1603: a phase 2 trial of ramucirumab plus irinotecan combination therapy as second-line treatment for patients with advanced gastric cancer.

[Poster session] ESMO World Congress on Gastrointestinal Cancer 2021. WEB, Jun 30-Jul 3, 2021

Saito R, Kawamoto Y, Yuki S, Sogabe S, Dazai M, Hosokawa A, Sawada K, Sato A, Nakamura M, Hatanaka K, Ishiguro A, Muto O, Shindo Y, Tsuji Y, Tateyama M, Ueda A, Sasaki T, Katagiri M, Sakamoto N, Komatsu Y.

Phase II trial of docetaxel and ramucirumab combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer (HGCSG1903).

[Poster session; Trials in progress] 2021 ASCO Annual Meeting. WEB, Jun 04-08, 2021

Kawamoto Y, Yuki S, Sawada K, Nakamura M, Muto O, Sogabe S, Shindo Y, Ishiguro A, Sato A, Tsuji Y, Dazai M, Okuda H, Sasaki T, Harada K, Nakano S, Nakatsumi H, Sekiguchi M, Sakata Y, Sakamoto N, Komatsu Y.

Results of a phase 2 trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603).

[Poster session] 2021 Gastrointestinal Cancers Symposium. WEB, Jan 15-17, 2021

2020年

Ishiguro A, Nakatsumi H, Muranaka T, Kawamoto Y, Yuki S, Tateyama M, Sato A, Miyagishima T, Nakamura M, Dazai M, Okuda H, Takahashi Y, Kobayashi T, Kato T, Hatanaka K, Amano T, Sakata Y, Komatsu Y HGCSG1301: A multicenter, double-blind, randomized controlled phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer treated with IRIS/Bev as second-line therapy: updated analysis of anti-tumor efficacy. Poster session 2020 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 23-25, 2020

Yuki S, Gamoh M, Denda T, Takashima A, Takahashi S, Nakamura M, Ohori H, Yamaguchi T, Kobayashi Y, Baba H, Kotake M, Amagai K, Kondo H, Shimada K, Sato A, Ishioka C, Komine K, Ouchi K, Morita S, Komatsu Y Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC). Poster session 2020 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 23-25, 2020

Nakano S, Kawamoto Y, Yuki S, Harada K, Sogabe S, Dazai M, Sato A, Ishiguro A, Nakamura M, Kajiura S, Takahashi Y, Karasaki H, Tateyama M, Hatanaka K, Tsuji Y, Sasaki T, Shindo Y, Kobayashi T, Sakata Y, Komatsu Y HGCSG1803: Single-arm phase II study evaluating efficacy of Oxaliplatin, Irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first line treatment. Poster session [Trials in progress] ASCO20 Virtual. WEB, May 29-31, 2020

Shindo Y, Nakatsumi H, Yuki S, Kawamoto Y, Muto O, Dazai M, Harada K, Kobayashi Y, Sogabe S, Katagiri M, Kotaka M, Nakamura M, Hatanaka K, Ishiguro A, Tsuji Y, Kobayashi T, Tateyama M, Sasaki Y, Sasaki T, Takagi R, Sakata Y, Komatsu Y HGCSG1801: A phase II trial of 2nd-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer (mCRC) refractory to anti-EGFR antibody. Poster session [Trials in progress] ESMO World Congress on Gastrointestinal Cancer 2020 VIRTUAL. WEB, Jul 1-4, 2020

Ando T, Ito K, Yuki S, Saito R, Nakano S, Nakatsumi H, Kawamoto Y, Dazai M, Miyashita K, Hatanaka K, Harada K, Miyagishima T, Hisai H, Ishiguro A, Ueda A, Kato T, Sasaki T, Shindo Y, Yokota I, Takagi R, Sakata Y, Komatsu Y HGCSG1902: Multicenter, prospective, observational study for cases with dysgeusia caused by chemotherapy for gastrointestinal cancer. Poster session [Trials in progress] ESMO World Congress on Gastrointestinal Cancer 2020 VIRTUAL. WEB, Jul 1-4, 2020

2019年

Nakano S, Kawamoto Y, Yuki S, Yagisawa M, Sawada K, Muranaka T, Nakatsumi H, Ishiguro A, Harada K, Kobayashi Y, Iwanaga I, Hatanaka K, Sakata Y, Komatsu Y Update result of HGCSG 1403: Phase I trial of oxaliplatin / irinotecan / S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancer. Poster session 2019 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 17-19, 2019

Ishiguro A, Kawamoto Y, Yuki S, Kobayashi Y, Harada K, Sogabe S, Tsuji Y, Nakano S, Sawada K, Muranaka T, Nakatsumi H, Dazai M, Sasaki T, Eto K, Nakamura M, Muto O, Sakata Y, Sakamoto N, Komatsu Y HGCSG1603: Phase II study of ramucirumab and irinotecan combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer. Poster session 2019 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 17-19, 2019

Nakamura M, Muranaka T, Yagisawa M, Kawamoto Y, Yuki S, Ishiguro A, Dazai M, Sogabe S, Harada K, Kobayashi Y, Miyagishima T, Okamura N, Tsuji Y, Ono K, Komatsu Y A Multicenter Prospective Study on the Efficacy and Safety of Denosumab in Gastrointestinal Cancer Patients Receiving Short-term Periodic Steroid Premedication for Prevention of Chemotherapy-induced Nausea and Vomiting (ESPRESSO-02/HGCSG1602). Poster session The WCO-IOF-ESCEO 2019. Paris (France), April 4-7, 2019

Ueda A, Muranaka T, Kawamoto Y, Sawada K, Nakatsumi H, Harada K, Miyagishima T, Hatanaka K, Dazai M, Kawahata S, Sasaki T, Sasaki Y, Kato S, Shinada K, Tsuji Y, Yuki S, Sakamoto N, Nishimoto N, Sakata Y, Komatsu Y Multi-centered Phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502). Poster session The ESMO 21st World Congress on Gastrointestinal Cancer. Barcelona (Spain), July 3-6, 2019

Ishiguro A, Yuki S, Takahashi N, Shichinohe T, Nakatsumi H, Kawamoto Y, Kusumi T, Harada K, Iwanaga I, Hatanaka K, Oomori K, Nakamura M, Senmaru N, Iwai K, Koike M, Sakamoto N, Taketomi A, Hirano S, Ito Y, Komatsu Y NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final Analysis. Poster session The ESMO 21st World Congress on Gastrointestinal Cancer. Barcelona (Spain), July 3-6, 2019

Sasaki Y, Muranaka T, Kawamoto Y, Sawada K, Nakatsumi H, Harada K, Miyagishima T, Hatanaka K, Dazai M, Ueda A, Sasaki T, Shinada K, Tsuji Y, Yuki S, Sakamoto N, Nishimoto N, Sakata Y, Komatsu Y Multi-centered Phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502). Poster session ESMO Asia Congress 2019. Singapore (Singapore), Nov 22-24, 2019

Tanimoto A, Yagisawa M, Nakano S, Kawamoto Y, Yuki S, Ishiguro A, Takahata T, Sato A, Iwanaga I, Ehira N, Uebayashi M, Muto O, Sasaki T, Hatanaka K, Tateyama M, Wakabayashi T, Dazai M, Minami S, Sakata Y, Komatsu Y HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P＋GEM) for unresectable locally advanced pancreatic cancer (LAPC). Poster session ESMO Asia Congress 2019. Singapore (Singapore), Nov 22-24, 2019

Nakamura M, Yuki S, Takahashi N, Shichinohe T, Nakatsumi H, Kawamoto Y, Kusumi T, Ishiguro A, Harada K, Iwanaga I, Hatanaka K, Oomori K, Senmaru N, Iwai K, Koike M, Sakamoto N, Taketomi A, Hirano S, Nishimoto N, Komatsu Y NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final Analysis. Poster session ESMO Asia Congress 2019. Singapore (Singapore), Nov 22-24, 2019

2018年

Ishiguro A, Yuki S, Nakatsumi H, Saiki T, Tsuji Y, Hatanaka K, Yoshita H, Minami S, Ohta T, Eto K, Nakajima J, Nakamura M, Suzuki K, Koike M, Kato K, Tateyama M, Asada C, Sekiguchi M, Sakata Y, Komatsu Y A Retrospective Cohort Study Evaluating the Safety and Efficacy of TAS-102 in Patients with Metastatic Colorectal Cancer [HGCSG1503]: Analysis of cases of prior regorafenib. Poster session 2018 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 18-20, 2018

Ogawa K, Yuki S, Kawamoto Y, Yagisawa M, Harada K, Okuda H, Furukawa K, Honda T, Dazai M, Kato T, Sasaki T, Shindo Y, Ota S, Sato A, Ueda A, Kato S, Fukunaga A, Nagai H, Sakata Y, Komatsu Y A Retrospective Cohort Study Evaluating the Safety and Efficacy of TAS-102 in Patients with Metastatic Colorectal Cancer [HGCSG1503]: Analysis of tumor location. Poster session 2018 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 18-20, 2018

Nakamura M, Komatsu Y, Muranaka T, Yagisawa M, Kawamoto Y, Nakatsumi H, Yuki S, Saiki T, Ishiguro A, Tateyama M, Kobayashi Y, Miyagishima T, Takahata T, Sato A, Dazai M, Okuda H, Fujikawa K, Eto K, Muto S, Hatanaka K, Amano T, Sakata Y HGCSG1301: A Multicenter, Double-Blind, Randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment. Poster session The ESMO 20th World Congress on Gastrointestinal Cancer. Barcelona (Spain), June 20-23, 2018

Ishiguro A, Kawamoto Y, Yuki S, Nakano S, Yagisawa M, Sawada K, Muranaka T, Hayashi H, Nakatsumi H, Saiki T, Harada K, Kobayashi Y, Iwanaga I, Hatanaka K, Sakata Y, Komatsu Y HGCSG 1403: Phase I trial of oxaliplatin / irinotecan / S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancer. Poster session The ESMO 20th World Congress on Gastrointestinal Cancer. Barcelona (Spain), June 20-23, 2018

Honda T, Yuki S, Muranaka T, Nakatsumi H, Tsuji Y, Miyagishima T, Yoshida S, Hatanaka K, Sasaki T, Ishiguro A, Muto O, Ohnuma H, Kato S, Sato A, Abe M, Kato K, Onodera K, Eto K, Tateyama M, Amano T, Sakata Y, Komatsu Y HGCSG1401: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer: Analysis of risk factors for liver dysfunction. Poster session The ESMO 20th World Congress on Gastrointestinal Cancer. Barcelona (Spain), June 20-23, 2018

Shindo Y, Yuki S, Yagisawa M, Kawamoto Y, Tsuji Y, Hatanaka K, Kobayashi Y, Kajiura S, Ishiguro A, Honda T, Dazai M, Eto K, Nakamura M, Koike M, Ota S, Sato A, Kato K, Ueda A, Fukunaga A, Sekiguchi M, Sakata Y, Komatsu Y HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of cases of prior regorafenib. Poster session The ESMO 20th World Congress on Gastrointestinal Cancer. Barcelona (Spain), June 20-23, 2018

Hatanaka K, Yuki S, Nakano S, Sawada K, Harada K, Okuda H, Ando T, Ogawa K, Furukawa K, Minami S, Saiki T, Ohta T, Kato T, Nakajima J, Sasaki T, Saitoh S, Shindo Y, Tateyama M, Kato S, Nagai H, Sakata Y, Komatsu Y HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index. Poster session The ESMO 20th World Congress on Gastrointestinal Cancer. Barcelona (Spain), June 20-23, 2018

Yuki S, Komatsu Y, Kawamoto Y, Nakatsumi H, Takahashi N, Shichinohe T, Okuda H, Ishiguro A, Harada K, Iwanaga I, Hatanaka K, Oomori K, Nakamura M, Senmaru N, Iwai K, Koike M, Shinohara T, Miyashita K, Ito Y, Taketomi A, Hirano S, Sakamoto N NORTH/HGCSG1003: A phase II study evaluating the safety and efficacy of FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer: Comparison with medical oncologist and surgeon. Poster session The ESMO 20th World Congress on Gastrointestinal Cancer. Barcelona (Spain), June 20-23, 2018

Nakamura M, Takashima A, Denda T, Gamoh M, Iwanaga I, Komatsu Y, Takahashi M, Ohori H, Sekikawa T, Tsuda M, Kobayashi Y, Miyamoto Y, Kotake M, Ishioka C, Shimada K, Sato A, Yuki S, Morita S, Takahashi S, Yamaguchi T Updated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer. Poster session ESMO 2018 Congress. Munich (Germany), Oct 19-23, 2018

Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Tokunaga S, Emi Y, Makiyama A, Kawamoto Y, Komatsu Y, Shimokawa M, Saeki H, Oki E, Baba H, Maehara Y Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B. Poster session ESMO 2018 Congress. Munich (Germany), Oct 19-23, 2018

Suzuki K, Yuki S, Nakano S, Kawamoto Y, Nakatsumi H, Hatanaka K, Ando T, Furukawa K, Ishiguro A, Ohta T, Eto K, Nakajima J, Nakamura M, Sogabe S, Kato K, Tateyama M, Kato S, Sekiguchi M, Sakata Y, Komatsu Y HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index. Poster session ESMO Asia 2018 Congress. Singapore (Singapore), Nov 23-25, 2018

Tsuji Y, Yuki S, Sawada K, Muranaka T, Kobayashi Y, Okuda H, Ogawa K, Minami S, Honda T, Dazai M, Kato T, Sasaki T, Shindo Y, Ota S, Sato A, Ueda A, Saitoh S, Nagai H, Sakata Y, Komatsu Y HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of cases of prior regorafenib. Poster session ESMO Asia 2018 Congress. Singapore (Singapore), Nov 23-25, 2018

Yoshikawa A, Kawamoto Y, Yuki S, Nakano S, Sawada K, Muranaka T, Nakatsumi H, Harada K, Kobayashi Y, Miyagishima T, Saiki T, Ishiguro A, Saito R, Ehira N, Iwanaga I, Hatanaka K, Abe N, Sakamoto N, Sakata Y, Komatsu Y HGCSG1403: Phase I trial of oxaliplatin / irinotecan / S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancer. Poster session ESMO Asia 2018 Congress. Singapore (Singapore), Nov 23-25, 2018

Ishiguro A, Yuki S, Nakano S, Kawamoto Y, Sawada K, Tsuji Y, Honda T, Miyagishima T, Yoshida S, Hatanaka K, Sasaki T, Muto O, Ohnuma H, Kato S, Sato A, Abe M, Kato K, Amano T, Sakata Y, Komatsu Y HGCSG1401: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer: Analysis of risk factors for liver dysfunction. Poster session ESMO Asia 2018 Congress. Singapore (Singapore), Nov 23-25, 2018

Dazai M, Yuki S, Sawada K, Muranaka T, Kawamoto Y, Nakatsumi H, Nakano S, Ishiguro A, Tateyama M, Sato A, Kobayashi Y, Nakamura M, Okuda H, Takahashi Y, Eto K, Muto S, Hatanaka K, Amano T, Sakata Y, Komatsu Y HGCSG1301: A Multicenter, Double-Blind, Randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment. Poster session ESMO Asia 2018 Congress. Singapore (Singapore), Nov 23-25, 2018

Iwanaga I, Yuki S, Kawamoto Y, Nakatsumi H, Takahashi N, Shichinohe T, Okuda H, Ishiguro A, Harada K, Hatanaka K, Oomori K, Nakamura M, Senmaru M, Iwai K, Koike M, Ito Y, Taketomi A, Hirano S, Sakamoto N, Komatsu Y NORTH/HGCSG1003: A phase II study evaluating the safety and efficacy of FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer: Comparison with medical oncologist and surgeon. Poster session ESMO Asia 2018 Congress. Singapore (Singapore), Nov 23-25, 2018

2017年

Nakamura M, Yagisawa M, Sawada K, Muranaka T, Nakatsumi H, Kawamoto Y, Yuki S, Dazai M, Ishiguro A, Kobayashi Y, Sogabe S, Miyagishima T, Iwanaga I, Tateyama M, Hatanaka K, Ono K, Sakamoto N, Sakata Y, Komatsu Y A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication for prevention of chemotherapy-induced nausea and vomiting (ESPRESSO-02/HGCSG1602 study). Poster session [Trials in progress] 2017 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 19-21, 2017

Kawamoto Y, Meguro T, Yuki S, Nakatsumi H, Sasaki T, Hatanaka K, Uebayashi M, Iwanaga I, Abe N, Nakamura M, Okuda H, Eto K, Oba A, Abe M, Muranaka T, Harada K, Oba K, Satoh T, Sakata Y, Komatsu Y Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab and failed: HGCSG1201. Poster session 2017 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 19-21, 2017

Shichinohe T, Yuki S, Takahashi N, Nakatsumi H, Kawamoto Y, Kusumi T, Ishiguro A, Sogabe S, Iwanaga I, Hatanaka K, Oomori K, Nakamura M, Senmaru N, Iwai K, Koike M, Sakamoto N, Taketomi A, Hirano S, Ito Y, Komatsu Y North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer (NORTH/HGCSG1003). Poster session 2017 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 19-21, 2017

Ota Y, Yuki S, Harada K, Yoshida S, Tsuji Y, Kobayashi Y, Hatanaka K, Okuda H, Sasaki T, Dazai M, Konno J, Ohta T, Honda T, Ishiguro A, Muto O, Sato Y, Kato S, Onodera K, Sakata Y, Komatsu Y A Retrospective Cohort Study Evaluating the Safety and Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer: HGCSG1401 - Updated analysis -. Poster session 2017 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 19-21, 2017

Shinozaki K, Yuki S, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Kobayashi K, Esaki T, Nakashima Y, Kubo N, Tokunaga S, Shimose T, Makiyama A, Saeki H, Oki E, Baba H, Maehara Y A phase II study (KSCC/HGCSG/CCOG/PerSeUS1501B) of trastuzumab plus S-1 and oxaliplatin for HER2-positive advanced gastric cancer. Poster session 2017 ASCO Annual Meeting. Chicago (USA), June 2-6, 2017

Sasaki T, Kawamoto Y, Yuki S, Meguro T, Hatanaka K, Uebayashi M, Iwanaga I, Nakamura M, Eto K, Okuda H, Abe M, Oba A, Abe N, Sato A, Nakatsumi H, Harada H, Muranaka T, Yagisawa M, Oba K, Sakata Y, Komatsu Y HGCSG1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab. Poster session 19th World Congress on Gastrointestinal Cancer. Barcelona (Spain), June 28-July 1, 2017

Dazai M, Yuki S, Nakatsumi H, Tsuji Y, Kobayashi Y, Hatanaka K, Okuda H, Hosokawa A, Furukawa K, Ogawa K, Minami S, Ishiguro A, Honda T, Ohta T, Eto K, Kato T, Nakajima J, Sasaki T, Nakamura M, Shindo Y, Sakata Y, Komatsu Y First report: A retrospective trial for evaluating the safety and efficacy of TAS-102 for patients with metastatic colorectal cancer: HGCSG1503. Poster session 19th World Congress on Gastrointestinal Cancer. Barcelona (Spain), June 28-July 1, 2017

Yuki S, Komatsu Y, Muranaka T, Tsuji Y, Harada K, Ota Y, Hatanaka K, Okuda H, Sasaki T, Dazai M, Konno J, Nakamura M, Ohta T, Honda T, Ishiguro A, Muto O, Kato S, Sato A, Abe M, Eto K, Sakamoto N, Sakata Y A Retrospective Cohort Study Evaluating the Safety and Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer [HGCSG1401]: Analysis of tumor location. Poster session 19th World Congress on Gastrointestinal Cancer. Barcelona (Spain), June 28-July 1, 2017

Yagisawa M, Nakamura M, Muranaka T, Nakatsumi H, Kawamoto Y, Yuki S, Sasaki T, Meguro T, Dazai M, Ishiguro A, Eto K, Harada K, Kobayashi Y, Miyagishima T, Iwanaga I, Uebayashi M, Hatanaka K, Sakamoto N, Sakata Y, Komatsu Y Multicenter prospective cohort study to evaluate of eye disorder induced by chemotherapy including S-1 (EyeDropS study/HGCSG1604). Poster session [Trials in progress] ESMO 2017 Congress. Madrid (Spain), Sep 08-12, 2017

Ishiguro A, Yuki S, Kawamoto Y, Nakatsumi H, Takahashi N, Shichinohe T, Kusumi T, Iwanaga I, Miyagishima T, Hatanaka K, Oomori K, Nakamura M, Senmaru N, Iwai K, Koike M, Sakamoto N, Taketomi A, Hirano S, Ito Y, Komatsu Y North Japan multicenter phase II study of FOLFOX as adjuvant chemotherapy for stage III colon cancer (NORTH/HGCSG1003) - Analysis of Tumor Location. Poster session ESMO 2017 Congress. Madrid (Spain), Sep 08-12, 2017

Yuki S, Komatsu Y, Yagisawa M, Tsuji Y, Harada K, Hatanaka K, Okuda H, Hosokawa A, Ogawa K, Furukawa K, Minami S, Ishiguro A, Honda T, Ohta T, Dazai M, Eto K, Sasaki T, Nakajima J, Sakamoto N, Sakata Y A Retrospective Cohort Study Evaluating the Safety and Efficacy of TAS-102 in Patients with Metastatic Colorectal Cancer [HGCSG1503]: Updated analysis. Poster session ESMO 2017 Congress. Madrid, Sep 08-12, 2017

Komatsu Y, Takashima A, Denda T, Gamoh M, Iwanaga I, Shimodaira H, Nakamura M, Yamaguchi T, Takahashi H, Kobayashi K, Tsuda M, Kobayashi Y, Baba H, Kotake M, Ishioka C, Sato A, Yuki S, Morita S, Takahashi S, Shimada K Treatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer. Oral presentation ESMO 2017 Congress. Madrid, Sep 08-12, 2017

Kawamoto Y, Yuki S, Meguro T, Hatanaka K, Uebayashi M, Iwanaga I, Nakamura M, Eto K, Okuda H, Abe M, Aonuma A, Abe N, Sato A, Nakatsumi H, Muranaka T, Yagisawa M, Oba K, Sakata Y, Sakamoto N, Komatsu Y HGCSG1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab. Poster session ESMO Asia 2017, Singapore (Singapore), Nov 17-19, 2017

Miyagishima T, Yuki S, Muranaka T, Tsuji Y, Ota Y, Hatanaka K, Okuda H, Sasaki T, Dazai M, Konno J, Nakamura M, Ohta T, Honda T, Ishiguro A, Muto O, Kato S, Sato A, Abe M, Sakata Y, Komatsu Y Analysis of tumor location: A retrospective trial for evaluating the safety and efficacy of Regorafenib for patients with metastatic colorectal cancer: HGCSG1401. Poster session ESMO Asia 2017, Singapore (Singapore), Nov 17-19, 2017

Yoshita H, Yuki S, Yagisawa M, Tsuji Y, Kobayashi Y, Hatanaka K, Okuda H, Dazai M, Furukawa K, Ogawa K, Minami S, Ishiguro A, Honda T, Ohta T, Eto K, Kato T, Nakajima J, Sasaki T, Sakata Y, Komatsu Y First report: A retrospective trial for evaluating the safety and efficacy of TAS-102 for patients with metastatic colorectal cancer: HGCSG1503. Poster session ESMO Asia 2017, Singapore (Singapore), Nov 17-19, 2017

2016年

Muranaka T, Yuki S, Sawada K, Kawamoto Y, Nakatsumi H, Dazai M, Hayashi H, Nakamura M, Ishiguro A, Sogabe S, Kobayashi Y, Miyagishima T, Iwanaga I, Tateyama M, Hatanaka K, Kato T, Sakamoto N, Sakata Y, Komatsu Y Phase II trial of bolus 5-FU/l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant unresectable gastric cancer (HGCSG1502). Poster session [Trials in progress] 2016 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 21-23, 2016

Kondo T, Yuki S, Kawamoto Y, Tsuji Y, Hosokawa A, Nakamura M, Muto O, Kato T, Iwanaga I, Hatanaka K, Sato A, Eto K, Furukawa K, Hayashi H, Tateyama M, Takahashi Y, Sogabe S, Honda T, Sakata Y, Komatsu Y Updated analysis: Phase II trial of Irinotecan/S-1/Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer (mCRC): HGCSG0902 - Comparison of administration interval in Cetuximab treatment. Poster session 2016 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 21-23, 2016

Muto O, Yuki S, Muranaka T, Kato T, Meguro T, Nakamura M, Sato A, Iwanaga I, Uebayashi M, Tatayema M, Hatanaka K, Eto K, Okuda H, Sogabe S, Abe M, Kato K, Kato S, Miyashita K, Sakata Y, Komatsu Y Observational Cohort Study of 1st line Bevacizumab Combined with Chemotherapy in Metastatic Colorectal Cancer (HGCSG0802): Sub-group Analysis by the GERCOR index. Poster session 2016 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 21-23, 2016

Nakamura M, Yuki S, Sawada K, Oba A, Sato A, Kato T, Meguro T, Ehira N, Tatayema M, Hatanaka K, Eto K, Okuda H, Kobayashi Y, Muto O, Abe M, Kato K, Kudo M, Miyashita K, Sakata Y, Komatsu Y Updated analysis: Observational Cohort Study of 1st line Bevacizumab Combined with Chemotherapy in Metastatic Colorectal Cancer (HGCSG0802): Sub-group Analysis by KRAS Exon2 Status. Poster session 2016 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 21-23, 2016

Yuki S, Nakatsumi H, Sawada K, Kato T, Meguro T, Nakamura M, Iwanaga I, Ehira N, Sonoda N, Kudo M, Kato K, Sogabe S, Amano T, Ono K, Sakamoto K, Miyamoto N, Kudo K, Sakamoto N, Sakata Y, Komatsu Y Observational Cohort Study of First-line Bevacizumab with Oxaliplatin or Irinotecan and Fluoropyrimidines in Metastatic Colorectal Cancer: HGCSG0802: Analysis of early tumor shrinkage (ETS). Poster session 2016 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 21-23, 2016

Muranaka T, Nakamura M, Ishiguro A, Yuki S, Murai T, Matsuda C, Oba A, Itaya K, Shigesawa T, Koike Y, Fujita Y, Endo A, Tsukuda Y, Ono Y, Kudo T, Nagasaka A, Nishikawa S, Komatsu Y Update analysis: Evaluation of the steroid premedication for cancer chemotherapy associated osteoporosis - ESPRESSO-01 study -. Poster session WCO-IOF-ESCEO 2016. Malaga (Spain), Apr 14-17, 2016

Miyamoto Y, Tanioka H, Tsuji A, Asayama M, Shiraishi T, Yuki S, Kotaka M, Makiyama A, Komatsu Y, Saeki H, Oki E, Emi Y, Baba H, Maehara Y A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402). Poster session 2016 ASCO Annual Meeting. Chicago (USA), June 3-7, 2016

Miyagishima T, Yuki S, Nakatsumi H, Kawamoto Y, Muranaka T, Sawada K, Kobayashi Y, Sasaki T, Nakamura M, Sato A, Iwanaga I, Tatayema M, Hatanaka K, Eto K, Okuda H, Muto O, Abe M, Oba A, Kato S, Miyashita K, Sakata Y, Komatsu Y Observational Cohort Study of 1st line Bevacizumab Combined with Chemotherapy in Metastatic Colorectal Cancer (HGCSG0802): Sub-group Analysis by the Glasgow Prognostic Score (GPS). Poster session 18th World Congress on Gastrointestinal Cancer. Barcelona (Spain), June 29-July 2, 2016

Yuki S, Komatsu Y, Nakatsumi H, Kawamoto Y, Muranaka T, Sawada K, Tsuji Y, Hosokawa A, Nakamura M, Muto O, Sasaki T, Iwanaga I, Hatanaka K, Sato A, Eto K, Furukawa K, Tateyama M, Takahashi Y, Sogabe S, Honda T, Sakamoto N, Sakata Y Final analysis: Phase II trial of Irinotecan/S-1/Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC: HGCSG0902 - Comparison of administration interval in Cetuximab treatment. Poster session 18th World Congress on Gastrointestinal Cancer. Barcelona (Spain), June 29-July 2, 2016

Nakatsumi H, Yuki S, Harada K, Muranaka T, Meguro T, Nakamura M, Iwanaga I, Oba A, Kudo M, Sogabe S, Ono K, Kudo K, Sakamoto N, Sakata Y, Komatsu Y Observational Cohort Study of First-line Bevacizumab with Oxaliplatin or Irinotecan and Fluoropyrimidines in Metastatic Colorectal Cancer: HGCSG0802: Analysis of early tumor shrinkage (ETS). Oral presentation 4th International Conference of Federation of Asian Clinical Oncology. Xiamen (China), Sep 22, 2016

Harada K, Yuki S, Tsuji Y, Hosokawa A, Nakamura M, Muto O, Sasaki T, Iwanaga I, Hatanaka K, Sato A, Takahashi Y, Sogabe S, Sakamoto N, Sakata Y, Komatsu Y Updated analysis: Phase II trial of Irinotecan/S-1/Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer (mCRC): HGCSG0902 - Comparison of administration interval in Cetuximab treatment. Oral presentation 4th International Conference of Federation of Asian Clinical Oncology. Xiamen (China), Sep 22, 2016

Yuki S, Komatsu Y, Satake H, Miyamoto Y, Tanioka H, Tsuji A, Asayama M, Shiraishi T, Kotaka M, Makiyama A, Kashiwada T, Takeuchi N, Shimokawa M, Saeki H, Oki E, Emi Y, Baba H, Maehara Y Updated report: A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402). Poster session ESMO 2016 Congress. Copenhagen (Denmark), Oct 7-11, 2016

Yuki S, Komatsu Y, Muranaka T, Harada K, Sugiyama J, Tsuji Y, Ando T, Hosokawa A, Hatanaka K, Naruse H, Takahata T, Sato A, Kobayashi Y, Miyagishima T, Okuda H, Kudo M, Nakamura M, Hisai H, Sakamoto N, Sakata Y Phase II trial of Panitumumab monotherapy for patients with KRAS exon2 wild type colorectal cancer after progression on Cetuximab: HGCSG1101. Poster session ESMO 2016 Congress. Copenhagen (Denmark), Oct 7-11, 2016

Sasaki T, Yuki S, Kawamoto Y, Harada K, Meguro T, Miyagishima T, Nakamura M, Sato A, Iwanaga I, Tatayema M, Hatanaka K, Eto K, Okuda H, Muto O, Abe M, Oba A, Kato S, Miyashita K, Sakata Y, Komatsu Y Observational Cohort Study of 1st line Bevacizumab Combined with Chemotherapy in Metastatic Colorectal Cancer (HGCSG0802): Sub-group Analysis by the Glasgow Prognostic Score (GPS). Poster session ESMO Asia 2016, Singapore (Singapore), Dec 16-19, 2016

Ando T, Yuki S, Nakatsumi H, Muranaka T, Hosokawa A, Tsuji Y, Nakamura M, Muto O, Sasaki T, Iwanaga I, Hatanaka K, Sato A, Eto K, Furukawa K, Tateyama M, Takahashi Y, Sogabe S, Honda T, Sakata Y, Komatsu Y Final analysis: Phase II trial of Irinotecan/S-1/Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902 -Comparison of administration interval in Cetuximab treatment. Poster discussion session ESMO Asia 2016, Singapore (Singapore), Dec 16-19, 2016

2015年

Komatsu Y, Yuki S, Nakatsumi H, Hosokawa A, Nakamura M, Muto O, Meguro T, Iwanaga I, Hatanaka K, Tsuji Y, Sato A, Eto K, Furukawa K, Onodera M, Tateyama M, Takahashi Y, Dazai M, Yokoyama S, Honda T, Sakata Y Phase II trial of Irinotecan plus S-1 (IRIS) with Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902 - Comparison of administration interval in Cetuximab treatment. Poster session 2015 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 15-17, 2015

Hosokawa A, Yuki S, Nakatsumi H, Hatanaka K, Tsuji Y, Okuda H, Takahashi Y, Konno J, Eto K, Kawamoto Y, Sonoda N, Sato Y, Saito M, Miyagishima T, Ikeda S, Yoshizaki K, Sasaki T, Saitoh S, Sakata Y, Komatsu Y Analysis of the GERCOR index in KRAS Exon2 WT patients with mCRC treated with salvage-line cetuximab-based chemotherapy: HGCSG0901. Poster session 2015 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 15-17, 2015

Sogabe S, Yuki S, Fukushima H, Takahashi N, Shichinohe T, Kusumi T, Nakamura F, Iwanaga I, Hatanaka K, Miyashita K, Konno J, Uemura K, Nenohi M, Kina M, Sakamoto N, Taketomi A, Hirano S, Amano T, Ito Y, Komatsu Y Safety analysis of FOLFOX as adjuvant chemotherapy for stage III colon cancer in phase II study (NORTH/HGCSG1003) - Detailed analysis of peripheral sensory neuropathy. Poster session 2015 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 15-17, 2015

Takahata T, Yuki S, Nakatsumi H, Harada K, Fukushima H, Sato A, Kato T, Meguro T, Nakamura M, Ehira N, Iwanaga I, Tateyama M, Hatanaka K, Eto K, Okuda H, Kobayashi Y, Muto O, Abe M, Sakata Y, Komatsu Y Observational Cohort Study of 1st line Bevacizumab Combined with Chemotherapy in Metastatic Colorectal Cancer (HGCSG0802): Sub-group Analysis by KRAS Exon2 Status. Poster session 2015 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 15-17, 2015

Iwanaga I, Yuki S, Fukushima H, Takahashi N, Shichinohe T, Kusumi T, Nakamura F, Sogabe S, Hatanaka K, Oomori K, Misawa K, Senmaru N, Iwai K, Shinohara T, Koike M, Miyashita K, Amano T, Ito Y, Sakamoto N, Taketomi A, Hirano S, Komatsu Y Safety analysis of FOLFOX as adjuvant chemotherapy for stage III colon cancer in phase II study (NORTH/HGCSG1003) - an analysis of surgeon vs oncologist. Poster session 17th World Congress on Gastrointestinal Cancer. Barcelona (Spain), July 1-4, 2015

Hatanaka K, Yuki S, Nakatsumi H, Hosokawa A, Nakamura M, Muto O, Meguro T, Iwanaga I, Tsuji Y, Sato A, Eto K, Furukawa K, Onodera M, Tateyama M, Takahashi Y, Dazai M, Yokoyama S, Honda T, Okuda H, Kudo M, Sakata Y, Komatsu Y Phase II trial of Irinotecan/S-1 (IRIS) with Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS WT metastatic colorectal cancer: HGCSG0902 - Comparison of administration interval in Cetuximab treatment. Poster session 17th World Congress on Gastrointestinal Cancer. Barcelona (Spain), July 1-4, 2015

Yagisawa M, Yuki S, Muranaka T, Sawada K, Hatanaka K, Kato T, Meguro T, Nakamura M, Iwanaga I, Eto K, Sato A, Okuda H, Kato K, Miyagishima T, Muto O, Yabusaki S, Miyamoto N, Kudo K, Sakata Y, Komatsu Y Association of morphologic response with overall survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: Updated analysis - HGCSG0802 -. Poster session European Cancer Congress 2015 (ECC 2015). Vienna (Austria), Sep 25-29, 2015

Nakatsumi H, Yuki S, Kawamoto Y, Muranaka T, Hatanaka K, Kato T, Meguro T, Nakamura M, Iwanaga I, Uebayashi M, Tateyama M, Eto K, Kudo M, Kato S, Okuda H, Sogabe S, Miyashita K, Sakata Y, Sakamoto N, Komatsu Y Updated analysis: Observational Cohort Study of 1st line Bevacizumab Combined with Chemotherapy in Metastatic Colorectal Cancer (HGCSG0802): Comparison of infusional FU/Oxaliplatin (OX)＋BV and oral FU/OX＋BV. Poster session European Cancer Congress 2015 (ECC 2015). Vienna (Austria), Sep 25-29, 2015

Kawamoto Y, Komatsu Y, Yuki S, Sawada K, Muranaka T, Nakatsumi H, Fukushima H, Ishiguro A, Dazai M, Hatanaka K, Nakamura M, Iwanaga I, Uebayashi M, Sogabe S, Miyagishima T, Ono K, Sakamoto N, Sakata Y Phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly for patients with advanced gastric cancer (HGCSG1404: SNOW study). Poster session [Trials in progress] ESMO Asia 2015. Singapore (Singapore), Dec 18-21, 2015

Hayashi H, Yuki S, Sawada K, Muranaka T, Kawamoto Y, Nakatsumi H, Komatsu Y Phase I trial of oxaliplatin/irinotecan/S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancer (HGCSG1403 study). Poster session [Trials in progress] ESMO Asia 2015. Singapore (Singapore), Dec 18-21, 2015

Dazai M, Yuki S, Muranaka T, Yoshida S, Ohta Y, Hatanaka K, Tsuji Y, Ohta T, Sato A, Eto K, Onodera K, Sato Y, Kato K, Nakamura M, Muto O, Ishiguro A, Tateyama M, Okuda H, Sakata Y, Komatsu Y A Retrospective Cohort Study Evaluating the Safety and Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer: the HGCSG1401 Study - First Report -. Poster session ESMO Asia 2015. Singapore (Singapore), Dec 18-21, 2015

Hosokawa A, Yuki S, Kawamoto Y, Ando T, Muto O, Nakamura M, Kato T, Iwanaga I, Hatanaka K, Tsuji Y, Sato A, Eto K, Furukawa K, Okuda H, Hayashi H, Fujikawa K, Kudo M, Honda T, Sakata Y, Komatsu Y Updated analysis: Phase II trial of Irinotecan plus S-1 (IRIS) with Cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902. Poster session ESMO Asia 2015. Singapore (Singapore), Dec 18-21, 2015

Ishiguro A, Yuki S, Kawamoto Y, Nakamura F, Takahashi N, Shichinohe T, Kusumi T, Sogabe S, Hatanaka K, Misawa K, Nenohi M, Hayashi H, Fukushima H, Takahashi M, Amano T, Ito Y, Sakamoto N, Taketomi A, Hirano S, Komatsu Y Safety analysis of FOLFOX as adjuvant chemotherapy for stage III colon cancer in phase II study (NORTH/HGCSG1003) - an analysis of surgeon vs oncologist. Poster session ESMO Asia 2015. Singapore (Singapore), Dec 18-21, 2015

Komatsu Y, Yuki S, Nakatsumi H, Sawada K, Hatanaka K, Kato T, Meguro T, Nakamura M, Iwanaga I, Uebayashi M, Tateyama M, Eto K, Kudo M, Kato K, Okuda H, Sogabe S, Miyagishima T, Miyashita K, Sakamoto N, Sakata Y Updated analysis: Observational Cohort Study of 1st line Bevacizumab Combined with Chemotherapy in Metastatic Colorectal Cancer (HGCSG0802): Comparison of infusional FU/Oxaliplatin (OX)＋BV and oral FU/OX＋BV. Poster session ESMO Asia 2015. Singapore (Singapore), Dec 18-21, 2015

Yuki S, Komatsu Y, Nakatsumi H, Muranaka T, Kobayashi Y, Miyagishima T, Ehira N, Iwanaga I, Okuda H, Tateyama M, Tsuji Y, Hatanaka K, Nakamura M, Kudo M, Fukushima H, Hisai H, Abe R, Sakamoto N, Oba K, Sakata Y Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type mCRC: Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP/HGCSG1001: Updated analysis of anti-tumor efficacy. Poster session ESMO Asia 2015. Singapore (Singapore), Dec 18-21, 2015

Hatanaka K, Yuki S, Nakatsumi H, Fukushima H, Naruse H, Kato T, Meguro T, Nakamura M, Iwanaga I, Uebayashi M, Tateyama M, Eto K, Kudo M, Kato S, Okuda H, Sogabe S, Miyashita K, Sakata Y, Komatsu Y Observational Cohort Study of 1st line Bevacizumab Combined with Chemotherapy in Metastatic Colorectal Cancer (HGCSG0802): Comparison of infusional FU/Oxaliplatin (OX)＋BV and oral FU/OX＋BV. Poster session 2015 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 15-17, 2015

Nakatsumi H, Yuki S, Muranaka T, Fukushima H, Kato T, Meguro T, Nakamura M, Iwanaga I, Ehira N, Sonoda N, Kudo M, Kato K, Miyashita K, Abe M, Sakamoto K, Miyamoto N, Kudo K, Sakamoto N, Sakata Y, Komatsu Y Association of early tumor shrinkage with progression free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802. Poster session 2015 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 15-17, 2015

Yuki S, Nakatsumi H, Hayashi H, Fukushima H, Kato T, Meguro T, Nakamura M, Iwanaga I, Eto K, Sato A, Okuda H, Oba A, Miyagishima T, Muto O, Yabusaki S, Miyamoto N, Kudo K, Sakamoto N, Sakata Y, Komatsu Y Association of morphologic response with progression free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802. Poster session 2015 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 15-17, 2015

Yuki S, Komatsu Y, Muranaka T, Hayashi H, Yoshida S, Ohta Y, Hatanaka K, Tsuji Y, Kawamoto Y, Yoshizaki K, Sato A, Eto K, Onodera K, Kato S, Nakamura M, Muto O, Abe M, Sato Y, Ishiguro A, Tateyama M, Okuda H, Sakamoto N, Sakata Y A Retrospective Cohort Study Evaluating the Safety and Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer: the HGCSG1401 Study - First Report -. Poster session 17th World Congress on Gastrointestinal Cancer. Barcelona (Spain), July 1-4, 2015

Kobayashi Y, Yuki S, Kawamoto Y, Sawada K, Miyagishima T, Ehira N, Iwanaga I, Okuda H, Tateyama M, Tsuji Y, Hatanaka K, Nakamura M, Kudo M, Fukushima H, Takagi T, Hisai H, Koike M, Abe R, Sakata Y, Komatsu Y Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP): Updated analysis of anti-tumor efficacy. Poster session European Cancer Congress 2015 (ECC 2015). Vienna (Austria), Sep 25-29, 2015

Nakamura M, Yuki S, Nakatsumi H, Muto O, Hosokawa A, Kato T, Iwanaga I, Hatanaka K, Tsuji Y, Sato A, Eto K, Furukawa K, Okuda H, Onodera M, Fujikawa K, Kudo M, Yokoyama S, Honda T, Sakata Y, Komatsu Y Updated analysis: Phase II trial of Irinotecan plus S-1 (IRIS) with Cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type of metastatic colorectal cancer (mCRC): HGCSG0902. Poster session European Cancer Congress 2015 (ECC 2015). Vienna (Austria), Sep 25-29, 2015

2014年

Iwanaga I, Komatsu Y, Kobayashi Y, Yuki S, Sakamoto N, Uebayashi M, Okuda H, Kusumi T, Sogabe S, Miyagishima T, Tateyama M, Tsuji Y, Hatanaka K, Nakamura M, Konno J, Yamamoto F, Iwai K, Onodera M, Oba K, Sakata Y Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP). Poster session 2014 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 16-18, 2014

Ueda A, Yuki S, Sasaki T, Kobayashi Y, Hosokawa A, Doi A, Tsuji Y, Okuda H, Kato T, Watanabe Y, Miyagishima T, Eto K, Ohta T, Takahata T, Ikeda S, Nakatsumi H, Iwai K, Kato K, Sakata Y, Komatsu Y Comparison of Cetuximab (Cmab) with Panitumumab (Pmab) monotherapy in salvage-line against KRAS wild type patients with metastatic colorectal cancer (mCRC): analysis of HGCSG0901 and 1002. Poster session 2014 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 16-18, 2014

Fukushima H, Yuki S, Nakatsumi H, Hayashi H, Harada K, Muranaka T, Nakamura M, Kawamoto Y, Kobayashi Y, Miyagishima T, Sogabe S, Tateyama M, Eto K, Hatanaka K, Ishiguro A, Okuda H, Takahashi Y, Iwanaga I, Sakata Y, Komatsu Y Randomized phase II trial of Hange-shasin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS＋Bev second-line treatment (HGCSG1301). Poster session [Trials in progress] ESMO 2014 Congress. Madrid (Spain), Sep 26-30, 2014

Kato S, Fukushima H, Kato K, Yuki S, Harada K, Kobayashi Y, Sasaki T, Ehira N, Iwanaga I, Uebayashi M, Dazai M, Sogabe S, Miyagishima T, Kudo M, Hatanaka K, Naruse H, Tateyama M, Sakata Y, Komatsu Y Exploratory randomized trial to evaluate the effect of indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV)/acute-onset diarrhea induced by IRIS/FOLFIRI - HGCSG0704 -. Poster session 2014 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 16-18, 2014

Doi A, Yuki S, Tsuji Y, Sasaki T, Fukushima H, Hatanaka K, Naruse H, Okuda H, Kusumi T, Fujikawa K, Takahashi Y, Saitoh S, Kajiura S, Hosokawa A, Watanabe Y, Yamamoto F, Kudo M, Akakura N, Sakata Y, Komatsu Y Analysis of Köhne’s prognostic index in KRAS wild type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901. Poster session 2014 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 16-18, 2014

Fujikawa K, Yuki S, Sasaki T, Harada K, Takahashi Y, Iwanaga I, Uebayashi M, Saitoh S, Koike M, Nakamura M, Sato Y, Kudo M, Tateyama M, Kawamoto Y, Hisai H, Saito M, Onodera M, Takagi T, Sakata Y, Komatsu Y Comparison of adding Cetuximab (Cmab) or Panitumumab (Pmab) to irinotecan (IRI)-based chemotherapy in salvage-line against KRAS wild type patients with metastatic colorectal cancer (mCRC): analysis of HGCSG0901 and 1002. Poster session 2014 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 16-18, 2014

Yuki S, Komatsu Y, Fukushima H, Sasaki T, Kobayashi Y, Harada K, Dazai M, Sogabe S, Miyagishima T, Ishiguro A, Takahata T, Sato A, Kudo M, Kato S, Kato K, Iwanaga I, Ehira N, Uebayashi M, Sakata Y Phase II trial of S-1 plus split Cisplatin (SSP) in patients with advanced gastric cancer (HGCSG0702): Final report. Poster session 2014 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 16-18, 2014

Yuki S, Komatsu Y, Fukushima H, Sasaki T, Kobayashi Y, Harada K, Amano T, Nakamura M, Kudo M, Tateyama M, Hatanaka K, Saitoh S, Miyagishima T, Kato T, Kawamoto Y, Takagi T, Iwanaga I, Miyashita K, Onodera M, Sakata Y The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Including multivariate analysis of two phase II studies. Poster session 2014 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 16-18, 2014

Kobayashi Y, Komatsu Y, Yuki S, Nakatsumi H, Fukushima H, Miyagishima T, Ehira N, Iwanaga I, Okuda H, Kusumi T, Tateyama M, Tsuji Y, Hatanaka K, Nakamura M, Kudo M, Takagi T, Hisai H, Abe R, Oba K, Sakata Y Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP) - Additional report of the efficacy analyses. Poster session 2014 ASCO Annual Meeting. Chicago (USA), May 30-Jun 03, 2014

Takahashi N, Yuki S, Fukushima H, Shichinohe T, Sasaki T, Kusumi T, Nakamura F, Miyagishima T, Iwanaga I, Hatanaka K, Oomori K, Misawa K, Senmaru N, Iwai K, Koike M, Shinohara T, Fukushima T, Ohno K, Tateyama M, Nishimoto N, Ito Y, Komatsu Y Safety analysis of FOLFOX as adjuvant chemotherapy for stage III colon cancer in North Japan multicenter phase II study (NORTH/HGCSG1003). Poster session 16th World Congress on Gastrointestinal Cancer. Barcelona (Spain), Jun 25-28, 2014

Yuki S, Komatsu Y, Harada K, Fukushima H, Sasaki T, Kobayashi Y, Tsuji Y, Naruse H, Okuda H, Takahashi Y, Hosokawa A, Konno J, Eto K, Kudo M, Kawamoto Y, Sonoda N, Sato Y, Uebayashi M, Kato T, Onodera M, Ohta T, Sakata Y Analysis of Glasgow Prognostic Score (GPS) in KRAS Exon2 wild type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901. Poster session 16th World Congress on Gastrointestinal Cancer. Barcelona (Spain), Jun 25-28, 2014

Nakamura M, Kobayashi Y, Yuki S, Nakatsumi H, Hayashi H, Iwanaga I, Tsuji Y, Hatanaka K, Okuda H, Konno J, Yamamoto F, Iwai K, Onodera M, Takagi T, Hisai H, Koike M, Abe R, Oba K, Sakata Y, Komatsu Y Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP): Additional analysis of QOL and skin toxicity. Poster session ESMO 2014 Congress. Madrid (Spain), Sep 26-30, 2014

Muto O, Yuki S, Fukushima H, Nakamura M, Hosokawa A, Kato T, Iwanaga I, Hatanaka K, Tsuji Y, Sato A, Eto K, Furukawa K, Okuda H, Onodera M, Fujikawa K, Kudo M, Yokoyama S, Honda T, Sakata Y, Komatsu Y First report of a phase II trial of Irinotecan plus S-1 (IRIS) with Cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type of metastatic colorectal cancer (mCRC): HGCSG0902. Poster session ESMO 2014 Congress. Madrid (Spain), Sep 26-30, 2014

2013年

Kawamoto Y, Yuki S, Akakura N, Sasaki T, Nakamura M, Nishikawa S, Hatanaka K, Naruse H, Saitoh S, Dazai M, Miyagishima T, Kato T, Meguro T, Sonoda N, Tateyama M, Takano M, Kudo M, Amano T, Sakata Y, Komatsu Y Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients with Metastatic Colorectal Cancer (mCRC) - Final analysis -: Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial. Poster session 22nd Asia Pacific Cancer Conference. Tianjin (China), Oct 31-Nov 02, 2013

Doi A, Sasaki T, Yuki S, Tsuji Y, Hatanaka K, Okuda H, Fujikawa K, Ando T, Iwanaga I, Kato T, Koike M, Watanabe Y, Nakamura M, Miyagishima T, Sato Y, Eto K, Kudo M, Ohta T, Sakata Y, Komatsu Y Comparison of cetuximab with panitumumab in salvage-line monotherapy against KRAS wild type patients with metastatic colorectal cancer: The integrated analyze of two retrospective trials - HGCSG0901 and HGCSG1002. Poster session 22nd Asia Pacific Cancer Conference. Tianjin (China), Oct 31-Nov 02, 2013

Dazai M, Fukushima H, Sato Y, Yuki S, Ohnuma H, Okuda H, Tsuji Y, Kawamoto Y, Hatanaka K, Iwanaga I, Koike M, Kato T, Nakamura M, Sogabe S, Fujikawa K, Hosokawa A, Hisai H, Tateyama M, Sakata Y, Komatsu Y Retrospective Cohort Study on the Safety and Efficacy of Panitumumab for Metastatic Colorectal Cancer Patients: The HGCSG1002 Study - Analysis of adverse events -. Poster session 2013 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 24-26, 2013

Sogabe S, Fukushima H, Yuki S, Kobayashi Y, Miyagishima T, Okuda H, Kusumi T, Doi A, Tsuji Y, Kawamoto Y, Ehira N, Koike M, Meguro T, Takahashi Y, Yoshizaki K, Muto S, Ishiguro A, Kato S, Sakata Y, Komatsu Y Retrospective Cohort Study on the Safety and Efficacy of Panitumumab (Pmab) for Metastatic Colorectal Cancer (mCRC) Patients: The HGCSG1002 Study - Analysis of clinical early predictor for the efficacy -. Poster session 2013 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 24-26, 2013

Kobayashi Y, Fukushima H, Sasaki T, Yuki S, Okuda H, Kusumi T, Doi A, Tsuji Y, Hatanaka K, Uebayashi M, Koike M, Kato T, Nakamura M, Sato Y, Ohta T, Kudo M, Konno J, Iwai K, Sakata Y, Komatsu Y Retrospective Cohort Study on the Safety and Efficacy of Panitumumab for Metastatic Colorectal Cancer Patients: The HGCSG1002 Study - Analysis of after Cetuximab refractory -. Poster session 2013 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 24-26, 2013

Iwanaga I, Yuki S, Fukushima H, Ishiguro A, Takahata T, Miyagishima T, Kudo M, Uehata Y, Sakata Y, Komatsu Y An open label, multi-center, phase II clinical trial to evaluate efficacy and safety of S-1 plus split Cisplatin in patients with advanced gastric cancer (AGC) - HGCSG0702: Safety analysis. Poster session 2013 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 24-26, 2013

Nakamura M, Yuki S, Dazai M, Kobayashi Y, Kato T, Naruse H, Kudo M, Akakura N, Sakata Y, Komatsu Y Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients with Metastatic Colorectal Cancer (mCRC): Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial - Comparison of the efficacy of KRAS status -. Poster session 2013 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 24-26, 2013

Sogabe S, Yuki S, Fukushima H, Miyagishima T, Ishiguro A, Takahata T, Kudo M, Uehata Y, Iwanaga I, Sakata Y, Komatsu Y An open, multi-center, phase II clinical trial to evaluate efficacy and safety of S-1 plus split Cisplatin (SSP) in patients with advanced gastric cancer (AGC) - HGCSG0702: Preliminary analysis. Oral presentation 10th International Gastric Cancer Congress. Verona (Italy), Jun 19-22, 2013

Saitoh S, Yuki S, Harada K, Nakamura M, Hatanaka K, Miyagishima T, Kudo M, Akakura N, Sakata Y, Komatsu Y Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients with Metastatic Colorectal Cancer (mCRC): Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial - Comparison of the efficacy of KRAS status -. Poster session European Cancer Congress 2013 (ECCO-ESMO-ESTRO). Amsterdam (Netherlands), Sep 27-Oct 01, 2013

Ishiguro A, Yuki S, Fukushima H, Sato A, Iwanaga I, Miyagishima T, Kudo M, Kato K, Sakata Y, Komatsu Y An open, multi-center, phase II clinical trial to evaluate efficacy and safety of S-1 plus split Cisplatin in patients with advanced gastric cancer (AGC) - HGCSG0702: Preliminary report. Poster session European Cancer Congress 2013 (ECCO-ESMO-ESTRO). Amsterdam (Netherlands), Sep 27-Oct 01, 2013

Hatanaka K, Yuki S, Sasaki T, Tsuji Y, Okuda H, Takahashi Y, Hosokawa A, Iwanaga I, Sakata Y, Komatsu Y Comparison of cetuximab with panitumumab in salvage-line monotherapy against KRAS wild type patients with metastatic colorectal cancer: Analysis of HGCSG0901 and HGCSG1002. Poster session European Cancer Congress 2013 (ECCO-ESMO-ESTRO). Amsterdam (Netherlands), Sep 27-Oct 01, 2013

Yuki S, Komatsu Y, Tsuji Y, Hatanaka K, Okuda H, Fujikawa K, Watanabe Y, Hosokawa A, Amano T, Sakata Y Analysis of Köhne’s prognostic index in KRAS wild type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901. Poster session European Cancer Congress 2013 (ECCO-ESMO-ESTRO). Amsterdam (Netherlands), Sep 27-Oct 01, 2013

Nakamura M, Yuki S, Kobayashi Y, Okuda H, Doi A, Tsuji Y, Hatanaka K, Iwanaga I, Koike M, Meguro T, Sogabe S, Ohnuma H, Takahashi Y, Ohta T, Hosokawa A, Hisai H, Yamamoto F, Kudo M, Sakata Y, Komatsu Y Retrospective cohort study on the safety and efficacy of Panitumumab (Pmab) for metastatic colorectal cancer (mCRC) patients: HGCSG1002 - Analysis of early clinical predictor for the efficacy -. Poster session 22nd Asia Pacific Cancer Conference. Tianjin (China), Oct 31-Nov 02, 2013

Fukushima H, Yuki S, Sasaki T, Note M, Kuno K, Tateyama M, Ishiguro A, Sato A, Akakura N, Munakata M, Hisai H, Ikeda S, Saito M, Nakatsumi H, Onodera M, Iwai K, Takagi T, Kato K, Sakata Y, Komatsu Y Retrospective comparison of adding cetuximab or panitumumab to irinotecan in salvage-line chemotherapy against KRAS wild type patients with metastatic colorectal cancer: The integrated analyze of two retrospective trials - HGCSG0901 and HGCSG1002. Poster session 22nd Asia Pacific Cancer Conference. Tianjin (China), Oct 31-Nov 02, 2013

Yuki S, Komatsu Y, Fukushima H, Doi A, Tsuji Y, Hatanaka K, Okuda H, Fujikawa K, Watanabe Y, Hosokawa A, Amano T, Eto K, Kudo M, Akakura N, Munakata M, Tateyama M, Sato Y, Miyagishima T, Uebayashi M, Sakata Y Analysis of Köhne’s prognostic index in KRAS wild type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901. Poster session [Young Investigator’s Award] 22nd Asia Pacific Cancer Conference. Tianjin (China), Oct 31-Nov 02, 2013

Ehira N, Yuki S, Iwanaga I, Uebayashi M, Harada K, Kobayashi Y, Sasaki T, Fukushima H, Ishiguro A, Takahata T, Sato A, Dazai M, Sogabe S, Miyagishima T, Takano M, Kudo M, Kato S, Kato K, Sakata Y, Komatsu Y An open, multi-center, phase II clinical trial to evaluate efficacy and safety of S-1 plus split Cisplatin in patients with advanced gastric cancer (AGC) - HGCSG0702: Preliminary report. Oral presentation [Young Investigator’s Award] 22nd Asia Pacific Cancer Conference. Tianjin (China), Oct 31-Nov 02, 2013

Yuki S, Komatsu Y, Fukushima H, Sasaki T, Amano T, Miyagishima T, Hatanaka K, Nakamura M, Tateyama M, Sakata Y Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients with Metastatic Colorectal Cancer (mCRC): Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial - Final analysis -. Poster session 2013 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 24-26, 2013

Shichinohe T, Komatsu Y, Akazawa K, Yuki S, Fukushima H, Ohno K, Nakamura F, Kusumi T, Morita T, Senmaru N, Kumagai N, Hirano S Randomized phase III clinical study comparing postoperative UFT/LV, UFT＋LV/UFT and UFT＋LV＋PSK/UFT＋PSK as adjuvant therapy for curatively resected stage III colorectal cancer (HGCSG-CAD study). Poster session 2013 ASCO Annual Meeting. Chicago (USA), May 31-Jun 04, 2013

Dazai M, Fukushima H, Sasaki T, Miyagishima T, Iwanaga I, Kudo M, Hatanaka K, Kato K, Sakata Y, Komatsu Y Randomized trial to explore indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV)/acute-onset diarrhea induced by IRIS/FOLFIRI: an exploratory trial - HGCSG0704 -. Poster session European Cancer Congress 2013 (ECCO-ESMO-ESTRO). Amsterdam (Netherlands), Sep 27-Oct 01, 2013

2012年

2012 Gastrointestinal Cancers Symposium Retrospective Cohort Study on the Safety and Efficacy of Cetuximab for Metastatic Colorectal Cancer Patients: The HGCSG0901 Study - Analysis of after Cetuximab refractory –. Satoshi Yuki, Yoshito Komatsu, Yasuyuki Kawamoto, Yasushi Tsuji, Hirohito Naruse, Ayumu Hosokawa, Takaya Kusumi, Atsushi Ishiguro, Soh Saito, Yuh Sakata：ポスター

Retrospective Cohort Study on the Safety and Efficacy of Cetuximab for Metastatic Colorectal Cancer Patients: The HGCSG0901 Study - Analysis of some predictive markers -. Kazuteru Hatanaka, Satoshi Yuki, Hiroshi Nakatsumi, Takahiro Kogawa, Hiraku Fukushima, Koshi Fujikawa, Yasushi Sato, Mayuko Saito, Masaki Munakata, Yoshito Komatsu：ポスター

Retrospective Cohort Study on the Safety and Efficacy of Bevacizumab for Metastatic Colorectal Cancer Patients: The HGCSG0801 Study – Efficacy of KRAS mutational status-. Susumu Sogabe, Satoshi Yuki, Hideyuki Hayashi, Hirohito Naruse, Michio Nakamura, Ichiro Iwanaga, Takashi Kato, Tomohumi Takagi, Hiroyuki Okuda, Yoshito Komatsu：ポスター

Retrospective Cohort Study on the Safety and Efficacy of Bevacizumab for Metastatic Colorectal Cancer Patients: The HGCSG0801 Study - Analysis of Bevacizumab Beyond Progression (BBP) -. Hiraku Fukushima, Satoshi Yuki, Yoshimitsu Kobayashi, Kazuteru Hatanaka, Takaya Kusumi, Ayumu Hosokawa, Takuto Miyagishima, Satoshi Takeuchi, Mineo Kudo, Yoshito Komatsu：ポスター

2012 ASCO Annual Meeting Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab(IRIS/Bev) in Patients with Metastatic Colorectal Cancer -Updated analysis-. Hokkaido Gastrointestinal Cancer Study Group(HGCSG) trial. Satoshi Yuki, Yoshito Komatsu, Takuto Miyagishima, Takashi Kato, Kazuteru Hatanaka, Michio Nakamura, Mineo Kudo, Nobuaki Akakura, Miki Tateyama, Yuh Sakata：ポスター

10th International Conference of the Asian Clinical Oncology Society 2012 Retrospective cohort study on the safety and efficacy of panitumumab for metastatic colorectal cancer patients：The HGCSG1002 study – Analysis of after cetuximab refractory -. Yoshimitsu Kobayashi, Yoshito Komatsu, Hideyuki Hayashi, Yasuyuki Kawamoto, Hiroshi Nakatsumi, Satoshi Yuki, Hiroyuki Okuda, Yasushi Tsuji, Kazuteru Hatanaka, Masahiko Koike, Takashi Kato, Michio Nakamura, Takuto Miyagishima, Yasushi Sato, Yasuo Takahashi, Tomoyuki Ohta, Tomokazu Nagasako, Shuichi Muto, Hiroyuki Hisai, Jun Konno：Oral Presentation

Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab(IRIS/Bev) in Patients with Metastatic Colorectal Cancer -Updated analysis-. Hokkaido Gastrointestinal Cancer Study Group(HGCSG) trial. Mineo Kudo, Satoshi Yuki, Yoshito Komatsu, Takuto Miyagishima, Takashi Kato, Kazuteru Hatanaka, Michio Nakamura, Nobuaki Akakura, Miki Tateyama, Yuh Sakata：ポスター

European Society of Medical Oncology (ESMO) 2012 Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab(IRIS/Bev) in Patients with Metastatic Colorectal Cancer -Updated analysis-. Hokkaido Gastrointestinal Cancer Study Group(HGCSG) trial. Kazuteru Hatanaka, Satoshi Yuki, Takuto Miyagishima, Takashi Kato, Michio Nakamura, Mineo Kudo, Miki Tateyama, Masahiro Asaka, Yuh Sakata, Yoshito Komatsu：ポスター

2013 Gastrointestinal Cancers Symposium An open, multi-center, phase II clinical trial to evaluate efficacy and safety of S-1 plus split Cisplatin in patients with advanced gastric cancer(AGC). - HGCSG0702 : Safety analysis. Ichiro Iwanaga, Satoshi Yuki, Hiraku Fukushima, Atsushi Ishiguro, Takenori Takahata, Takuto Miyagishima, Mineo Kudo, Yasuko Uehata, Yuh Sakata, Yoshito Komatsu：ポスター

Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients with Metastatic Colorectal Cancer (mCRC) - Final analysis - : Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial. Satoshi Yuki, Yoshito Komatsu, Hiraku Fukushima, Takahide Sasaki, Toraji Amano, Takuto Miyagishima, Kazuteru Hatanaka, Michio Nakamura, Miki Tateyama, Yuh Sakata：ポスター

Retrospective Cohort Study on the Safety and Efficacy of Panitumumab for Metastatic Colorectal Cancer Patients: The HGCSG1002 Study – Analysis of after Cetuximab refractory–. Yoshimitsu Kobayashi, Hiraku Fukushima, Takahide Sasaki, Satoshi Yuki, Hiroyuki Okuda, Takaya Kusumi, Ayako Doi, Yasushi Tsuji, Kazuteru Hatanaka, Minoru Uebayashi, Masahiko Koike, Takashi Kato, Michio Nakamura, Yasushi Sato, Tomoyuki Ohta1, Mineo Kudo, Jun Konno, Kazuhiro Iwai, Yuh Sakata, Yoshito Komatsu：ポスター

Fukushima H, Yuki S, Kobayashi Y, Hatanaka K, Kusumi T, Hosokawa A, Miyagishima T, Takeuchi S, Kudo M, Komatsu Y Retrospective Cohort Study on the Safety and Efficacy of Bevacizumab for Metastatic Colorectal Cancer Patients: The HGCSG0801 Study - Analysis of Bevacizumab Beyond Progression (BBP) -. Poster session 2012 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 19-21, 2012

Sogabe S, Yuki S, Hayashi H, Naruse H, Nakamura M, Iwanaga I, Kato T, Takagi T, Okuda H, Komatsu Y Retrospective Cohort Study on the Safety and Efficacy of Bevacizumab for Metastatic Colorectal Cancer Patients: The HGCSG0801 Study - Efficacy of KRAS mutational status -. Poster session 2012 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 19-21, 2012

Hatanaka K, Yuki S, Nakatsumi H, Kogawa T, Fukushima H, Fujikawa K, Sato Y, Saito M, Munakata M, Komatsu Y Retrospective Cohort Study on the Safety and Efficacy of Cetuximab for Metastatic Colorectal Cancer Patients: The HGCSG0901 Study - Analysis of some predictive markers -. Poster session 2012 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 19-21, 2012

Yuki S, Komatsu Y, Kawamoto Y, Tsuji Y, Naruse H, Hosokawa A, Kusumi T, Ishiguro A, Saitoh S, Sakata Y Retrospective Cohort Study on the Safety and Efficacy of Cetuximab for Metastatic Colorectal Cancer Patients: The HGCSG0901 Study - Analysis of after Cetuximab refractory -. Poster session 2012 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 19-21, 2012

Yuki S, Komatsu Y, Miyagishima T, Kato T, Hatanaka K, Nakamura M, Kudo M, Akakura N, Tateyama M, Sakata Y Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients with Metastatic Colorectal Cancer - Updated analysis - Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial. Poster session 2012 ASCO Annual Meeting. Chicago (USA), Jun 01-05, 2012

Kudo M, Yuki S, Komatsu Y, Miyagishima T, Kato T, Hatanaka K, Nakamura M, Akakura N, Tateyama M, Sakata Y Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients with Metastatic Colorectal Cancer - Updated analysis - Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial. Poster session 10th International Conference of the Asian Clinical Oncology Society. Seoul (Korea), Jun 13-15, 2012

Kobayashi Y, Komatsu Y, Hayashi H, Kawamoto Y, Nakatsumi H, Yuki S, Okuda H, Tsuji Y, Hatanaka K, Koike M, Kato T, Nakamura M, Miyagishima T, Sato Y, Takahashi Y, Ohta T, Nagasako T, Muto S, Hisai H, Konno J Retrospective cohort study on the safety and efficacy of panitumumab for metastatic colorectal cancer patients: The HGCSG1002 study - Analysis of after cetuximab refractory -. Oral presentation 10th International Conference of the Asian Clinical Oncology Society. Seoul (Korea), Jun 13-15, 2012

Hatanaka K, Yuki S, Miyagishima T, Kato T, Nakamura M, Kudo M, Tateyama M, Asaka M, Sakata Y, Komatsu Y Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients with Metastatic Colorectal Cancer - Updated analysis - Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial. Poster session ESMO 2012 Congress. Vienna (Austria), Sep 28-Oct 02, 2012

Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab(IRIS/Bev) in Patients with Metastatic Colorectal Cancer (mCRC) : Hokkaido Gastrointestinal Cancer Study Group(HGCSG) trial. – Comparison of the efficacy of KRAS status -. Michio Nakamura, Satoshi Yuki, Masayoshi Dazai, Yoshimitsu Kobayashi, Takashi Kato, Hirohito Naruse, Mineo Kudo, Nobuaki Akakura, Yuh Sakata, Yoshito Komatsu：ポスター

2011年

2011 Gastrointestinal Cancers Symposium The optimal dose period of indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV) induced by mFOLFOX6: an exploratory trial –HGCSG0703-. Satoshi Yuki, Hiroshi Nakatsumi, Miki Tateyama, Yasuko Uehata, Mineo Kudo, Kanji Kato, Takuto Miyagishima, Minoru Uebayashi, Masahiro Asaka, Yoshito Komatsu：ポスター

Yuki S, Nakatsumi H, Tateyama M, Uehata Y, Kudo M, Kato K, Miyagishima T, Uebayashi M, Asaka M, Komatsu Y The optimal dose period of indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV) induced by mFOLFOX6: an exploratory trial - HGCSG0703 -. Poster session 2011 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 20-22, 2011

Iwanaga I, Yuki S, Miyagishima T, Hosokawa A, Kato T, Komatsu Y Retrospective Cohort Study on the Safety and Efficacy of Bevacizumab for Metastatic Colorectal Cancer Patients: The HGCSG0801 Study - Analysis of Bevacizumab Beyond Progression (BBP) -. Poster session 21st Asia Pacific Cancer Conference. Kuala Lumpur (Malaysia), Nov 10-12, 2011

Yuki S, Komatsu Y, Kogawa T, Hatanaka K, Kusumi T, Fujikawa K Retrospective Cohort Study on the Safety and Efficacy of Cetuximab for Metastatic Colorectal Cancer Patients: The HGCSG0901 Study - Analysis of some predictive markers -. Poster session 21st Asia Pacific Cancer Conference. Kuala Lumpur (Malaysia), Nov 10-12, 2011

21st Asia Pacific Cancer Conference 2011 Retrospective Cohort Study on the Safety and Efficacy of Bevacizumab for Metastatic Colorectal Cancer Patients: The HGCSG0801 Study - Analysis of Bevacizumab Beyond Progression (BBP) -. Ichiro Iwanaga, Satoshi Yuki, Takuto Miyagishima, Ayumu Hosokawa, Takashi Kato, Yoshito Komatsu：ポスター

Retrospective Cohort Study on the Safety and Efficacy of Cetuximab for Metastatic Colorectal Cancer Patients: The HGCSG0901 Study - Analysis of some predictive markers -. Satoshi Yuki, Yoshito Komatsu, Takahiro Kogawa, Kazuteru Hatanaka, Takaya Kusumi, Koshi Fujikawa：ポスター

2010年

9th Asian Clinical Oncology Society 2010 The optimal dose period of indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV) induced by mFOLFOX6: an exploratory trial –HGCSG0703-. Hiroshi Nakatsumi, Satoshi Yuki, Susumu Sogabe, Norikazu Sonoda, Shuichi Muto, Masatoshi Takano, Mineo Kudo, Kanji Kato, Hisashi Oda, Takuto Miyagishima, Minoru Uebayashi, Takashi Meguro, Masahiro Asaka, Yoshito Komatsu：Oral Presentation

European Society of Medical Oncology (ESMO) 2010 Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab in Patients with Metastatic Colorectal Cancer. Yoshito Komatsu, Satoshi Yuki, Susumu Sogabe, Michio Nakamura, Kazuteru Hatanaka, Takuto Miyagishima, Mineo Kudo, Masaki Munakata, Yuh Sakata, Masahiro Asaka：ポスター

Nakatsumi H, Yuki S, Sogabe S, Sonoda N, Muto S, Takano M, Kudo M, Kato K, Oda H, Miyagishima T, Uebayashi M, Meguro T, Asaka M, Komatsu Y The optimal dose period of indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV) induced by mFOLFOX6: an exploratory trial - HGCSG0703 -. Oral presentation 9th Asian Clinical Oncology Society. Gifu (Japan), Aug 25-27, 2010

Komatsu Y, Yuki S, Sogabe S, Nakamura M, Hatanaka K, Miyagishima T, Kudo M, Munakata M, Sakata Y, Asaka M Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab in Patients with Metastatic Colorectal Cancer. Poster session ESMO 2010 Congress. Milan (Italy), Oct 9-12, 2010

2009年

2009 Gastrointestinal Cancers Symposium Phase II Study of Combination With Irinotecan and S-1(IRIS) for Inoperable Recurrent Advanced Colorectal Cancer(HGCSG0302). Final analysis. Satoshi Yuki, Yoshito Komatsu, Susumu Sogabe, Ichiro Iwanaga, Mineo Kudo, Takuto Miyagishima, Michio Nakamura, Kazuteru Hatanaka, Masahiro Asaka, Yuh Sakata：ポスター

ECCO 15-34th ESMO 2009 Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab in Patients with Metastatic Colorectal Cancer. Kazuteru Hatanaka, Yoshito Komatsu, Satoshi Yuki, Michio Nakamura, Takuto Miyagishima, Mineo Kudo, Masaki Munakata, Yuh Sakata, Masahiro Asaka：ポスター

Yuki S, Komatsu Y, Sogabe S, Iwanaga I, Kudo M, Miyagishima T, Nakamura M, Hatanaka K, Asaka M, Sakata Y Phase II Study of Combination with Irinotecan and S-1 (IRIS) for Inoperable Recurrent Advanced Colorectal Cancer (HGCSG0302): Final analysis. Poster session 2009 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 15-17, 2009

Hatanaka K, Komatsu Y, Yuki S, Nakamura M, Miyagishima T, Kudo M, Munakata M, Sakata Y, Asaka M Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab in Patients with Metastatic Colorectal Cancer. Poster session ECCO 15-34th ESMO Multidisciplinary Congress. Berlin (Germany), Sep 20-24, 2009

20th Asia Pacific Cancer Conference 2009 Safety and efficacy analysis of bevacizumab chemotherapy for metastatic colorectal cancer patients(HGCSG0801). Susumu Sogabe, Satoshi Yuki, Ichiro Iwanaga, Satoshi Takeuchi, Michio Nakamura, Hideyuki Hayashi, Kazuteru Hatanaka, Masatoshi Takano, Shuichi Muto, Kanji Kato, Kencho Miyashita, Yutaka Watanabe, Yuji Tsukioka, Ayumu Hosokawa, Takashi Kato, Takashi Meguro, Takuto Miyagishima, Takaya Kusumi, Masao Hosokawa, Masahiro Asaka, Yoshito Komatsu：ポスター

Sogabe S, Yuki S, Iwanaga I, Takeuchi S, Nakamura M, Hayashi H, Hatanaka K, Takano M, Muto S, Kato K, Miyashita K, Watanabe Y, Tsukioka Y, Hosokawa A, Kato T, Meguro T, Miyagishima T, Kusumi T, Hosokawa M, Asaka M, Komatsu Y Safety and efficacy analysis of bevacizumab chemotherapy for metastatic colorectal cancer patients (HGCSG0801). Poster session 20th Asia Pacific Cancer Conference. Tsukuba (Japan), Nov 12-14, 2009

2008年

K. Shitara, Y. Komatsu, S. Yuki, M. Munakata, O. Muto, S. Shimaya, Y. Sakata. Pilot study of combination chemotherapy with S-1 and irinotecan (IRIS) for advanced pancreatic cancer. 2008 Gastrointestinal Cancers Symposium(abstr 155) (Orlando, USA)

Shitara K, Komatsu Y, Yuki S, Munakata M, Muto O, Shimaya S, Sakata Y Pilot study of combination chemotherapy with S-1 and irinotecan (IRIS) for advanced pancreatic cancer. Poster session 2008 Gastrointestinal Cancers Symposium. Orlando (USA), Jan 25-27, 2008

2007年

Y. Komatsu, S. Yuki, I. Iwanaga, M. Kudo, M. Tateyama, T. Amano, Y. Sakata, M. Asaka. Phase II clinical study of combination therapy with irinotecan and S-1(IRIS) for inoperable recurrent advanced colorectal cancer (2nd report): For Hokkaido Gastrointestinal Cancer Study Group (HGCSG).

S. Yuki, Y. Komatsu, N. Machida, M. Ozasa, K. Nishi, T. Miyagishima, T. Kato, M. Nakamura, M. Asaka, Y. Sakata. Phase II Study of Combination With Irinotecan and S-1(IRIS) for Inoperable Recurrent Advanced Colorectal Cancer(HGCSG0302). Safety analysis. 2007 ECCO14 (abstr 3053)(Barcelona, Spain)

Yuki S, Komatsu Y, Machida N, Ozasa M, Nishi K, Miyagishima T, Kato T, Nakamura M, Asaka M, Sakata Y Phase II Study of Combination with Irinotecan and S-1 (IRIS) for Inoperable Recurrent Advanced Colorectal Cancer (HGCSG0302): Safety analysis. Poster session The European Cancer Conference (ECCO14). Barcelona (Spain), Sep 23-27, 2007

2006年

Y. Komatsu, S. Yuki, M. Kudo, M. Tateyama, K. Nishi, K. Miyashita, H. Akita, Y. Sakata, T. Meguro, M. Asaka. Phase II clinical study of combination therapy with CPT-11 and S-1 for inoperable, recurrent, advanced colorectal cancer for Hokkaido Gastrointestinal Cancer Study Group: HGCSG0302. 2006 Gastrointestinal Cancers Symposium(abstr 265)(San Francisco, USA)

Y. Komatsu, S. Yuki, H. Akita, M. Kudo, M. Tateyama, T. Saga, T. Meguro, G. Suzuki, Y. Sakata, M. Asaka. Phase II clinical study of combination therapy with irinotecan and S-1(IRIS) for inoperable recurrent advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group study HGCSG-0302). 2006 ASCO Annual Meeting (abstr 3589)(Atlanta, USA)

Komatsu Y. Current standard therapy and clinical studies for gastric cancer in Japan. Advisory Board Meeting Cetuximab Gastrointestinal Carcinoma, 2006 (Bangkok, Thailand)

Komatsu Y, Yuki S, Fuse N, Iwanaga I, Kudo M, Tateyama M,Meguro T,Suzuki G,Amano T,Asaka M. Phase II clinical study of combination therapy with irinotecan and S-1 (IRIS) for inoperable recurrent advanced colorectal cancer. 14th United European Gastroenterology Week (UEGW) 2006 (Berlin, Germany)

Yuki S, Komatsu Y, Fuse N, Tateyama M, Nishi K, Kato T, Kudo M, Miyagishima T, Asaka M, Sakata Y Phase I/II study of docetaxel, cisplatin and 5-fluorouracil (TPF) as first-line chemotherapy in Japanese patients with advanced esophageal cancer. Poster session 2006 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 26-28, 2006

Komatsu Y, Yuki S, Kudo M, Tateyama M, Nishi K, Miyashita K, Akita H, Sakata Y, Meguro T, Asaka M Phase II clinical study of combination therapy with CPT-11 and S-1 for inoperable, recurrent, advanced colorectal cancer for Hokkaido Gastrointestinal Cancer Study Group: HGCSG0302. Poster session 2006 Gastrointestinal Cancers Symposium. San Francisco (USA), Jan 26-28, 2006

Komatsu Y, Yuki S, Fuse N, Iwanaga I, Kudo M, Tateyama M, Meguro T, Sakata Y, Asaka M Phase II clinical study of combination therapy with irinotecan and S-1 (IRIS) for inoperable recurrent advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group study (HGCSG0302). Poster session 2006 ASCO Annual Meeting. Orlando (USA), Jun 2-6, 2006

Komatsu Y, Yuki S, Fuse N, Iwanaga I, Kudo M, Tateyama M, Meguro T, Suzuki G, Amano T, Asaka M Phase II clinical study of combination therapy with irinotecan and S-1 (IRIS) for inoperable recurrent advanced colorectal cancer. Poster session 14th United European Gastroenterology Week. Berlin (Germany), Oct 21-25, 2006

2005年

Komatsu Y, Yuki S, Uehata Y, Kato S, Nakamura M, Kato K, Amano T, Tateyama M, Miyagishima T, Kudo M, Akita H, Sakata Y, Asaka M. Efficacy of combined therapy with irinotecan and S-1 for advanced colorectal cancer (Phase II Study) France-Japanese Meeting on Cancer Chemotherapy, 2005 (Sapporo, Japan)

Komatsu Y, Yuki S, Machida N, Tateyama M, Kudo M, Akita H, Sakata Y, Asaka M. Efficacy of combined Therapy with irinotecan and S-1 for advanced colorectal cancer. 18th ASIA PACIFIC CANCER CONFERENCE, 2005 (Seoul, Korea)

Komatsu Y, Yuki S, Machida N, Tateyama M, Kudo M, Akita H, Sakata Y, Asaka M Efficacy of Combined Therapy with Irinotecan and S-1 for Advanced Colorectal Cancer. Poster session 18th Asia Pacific Cancer Conference. Seoul (Korea), Sep 7-9, 2005

Komatsu Y, Yuki S, Uehata Y, Kato K, Nakamura M, Kato S, Amano T, Ozasa M, Kato M, Tateyama M, Kudo M, Akita H, Sakata Y, Asaka M Phase II clinical study of combination therapy with CPT-11 and S-1 for inoperable recurrent advanced colorectal cancer. Poster session 13th United European Gastroenterology Week. Copenhagen (Denmark), Oct 15-19, 2005

2004年

Komatsu Y., Yuki S., Machida N., Miyashita K., Miyagishima T., Kudo M., Kunieda Y., Tateyama M., Wakahama O., Meguro T., Oizumi H., Watanabe M., Akita H., Asaka M. and Sakata Y. Phase I/II clinical and pharmacokinetic studies of irinotecan and oral S-1 in patients with advanced gastric cancer for Hokkaido Gastrointestinal Cancer Study Group 12th United European Gastroenterology Week, 2004 (Prague, Checo)

Komatsu Y, Yuki S, Machida N, Miyashita K, Miyagishima T, Kudo M, Kunieda Y, Tateyama M, Wakahama O, Meguro T, Oizumi H, Watanabe M, Akita H, Asaka M, Sakata Y Phase I/II clinical and pharmacokinetic studies of irinotecan and oral S-1 in patients with advanced gastric cancer for Hokkaido Gastrointestinal Cancer Study Group. Poster session 12th United European Gastroenterology Week. Prague (Czech Republic), Sep 25-29, 2004

2002年

Y. Komatsu, H. Takeda, M. Takei, T. Kato, M. Tateyama, T. Miyagishima, Y. Kunieda, O. Wakahama, S. Hashino, T. Sugiyama, M. Kato, M. Asaka, Y. Sakata. A phase I and PK study of S-1 and irinotecan (CPT-11) in patients with advanced gastric cancer (AGC). 2002 ASCO Annual Meeting (abstr 683)(Orlando, USA)

Komatsu Y, Takeda H, Takei M, Kato T, Tateyama M, Miyagishima T, Kunieda Y, Wakahama O, Hashino S, Sugiyama T, Kato M, Asaka M, Sakata Y A phase I and PK study of S-1 and irinotecan (CPT-11) in patients with advanced gastric cancer (AGC). Poster session 2002 ASCO Annual Meeting. Orlando (USA), May 18-21, 2002

2024年

Hiroshi Nakatsumi, Kazuaki Harada, Satoshi Yuki, Kentaro Sawada, Atsushi Ishiguro, Susumu Sogabe, Takayuki Ando, Yusuke Sasaki, Ayumu Yoshikawa, Michio Nakamura, Masayoshi Dazai, Miki Tateyama, Osamu Muto, Masahito Kotaka, Tamotsu Sagawa, Kazuteru Hatanaka, Ryo Takagi, Yuh Sakata, Yoshito Komatsu

Phase II study of FOLFIRI plus aflibercept for colorectal cancer refractory to anti-EGFR antibodies: HGCSG1801

第21回日本臨床腫瘍学会学術集会, 2024/02/22 - 24, 名古屋

Shintaro Nakano, Yasuyuki Kawamoto, Kentaro Sawada, Takuto Miyagishima, Susumu Sogabe, Yoshimitsu Kobayashi, Ken Ito, Atsushi Sato, Chen Yu, Masayoshi Dazai, Kazuaki Harada, Satoshi Yuki, Isao Yokota, Yoshito Komatsu

HGCSG 1803: Phase 2 study evaluating efficacy of OX-IRIS in metastatic pancreatic cancer as first line therapy

第21回日本臨床腫瘍学会学術集会, 2024/02/22 - 24, 名古屋

2023年

伊藤　憲，結城　敏志，川本　泰之，原田　一顕，八木澤　允貴，澤田　憲太郎，石黒　敦，畑中　一映，奥田　博介，笹木　有佑，加藤　総介，太宰　昌佳，小松　嘉人

HGCSG1901：転移性結腸直腸癌に対するIRIS/Bev療法の有効性、安全性に関する多施設共同後方視的観察研究

第132回　日本消化器病学会北海道支部例会, 2023/03/04-05, 札幌

2022年

川本　泰之，原田　一顕，中村　路夫，曽我部　進，澤田　憲太郎，武藤　理，進藤　吉明，結城　敏志，佐藤　温，石黒　敦，奥田　博介，辻　靖，太宰　昌佳，小松　嘉人

HGCSG1603：Ramucirumab plus irinotecan as second-line treatment for advanced gastric cancer

[ワークショップ] 第95回　日本胃癌学会総会, 2023/02/23-25, 札幌

Osamu Muto, Kazuaki Harada, Takahiro Yamamura, Michio Nakamura, Susumu Sogabe, Kentaro Sawada, Shintaro Nakano, Masataka Yagisawa, Tetsuhito Muranaka, Masayoshi Dazai, Miki Tateyama, Yasuyuki Kawamoto, Satoshi Yuki, Yuh Sakata, Yoshito Komatsu

HGCSG2101：膵癌リポソーマルイリノテカン・5FU/LV療法におけるUGT1A1タイプ別の解析

[一般口演] 第60回　日本癌治療学会学術集会，2022/10/20-22, 神戸+web

Yokoyama T, Ito K, Yuki S, Nakatsumi H, Ando T, Sawada K, Yagisawa M, Ishiguro A, Dazai M, Iwanaga I, Hatanaka K, Sato A, Matsumoto R, Shindo Y, Tateyama M, Muranaka T, Katagiri M, Yokota I, Sakata Y, Komatsu Y.

HGCSG1902: Multicenter, prospective, observational study for cases with dysgeusia caused by chemotherapy.

[一般口演] 第19回日本臨床腫瘍学会学術集会. 京都. Feb 17-19, 2022

Dazai M, Harada K, Yamamura T, Muto O, Nakamura M, Sogabe S, Sawada K, Yagisawa M, Muranaka T, Nakano S, Tateyama M, Ito K, Saito R, Kobayashi Y, Kato S, Miyagishima T, Kawamoto Y, Yuki S, Sakata Y, Komatsu Y.

HGCSG2101: A real-world analysis of nanoliposomal irinotecan plus 5-FU/LV in pancreatic ductal adenocarcinoma.

[Mini-Oral Session] 第19回日本臨床腫瘍学会学術集会. 京都. Feb 17-19, 2022

2021年

Ishiguro A, Ito K, Yuki S, Harada K, Saito R, Muto O, Hatanaka K, Okuda H, Sasaki Y, Nakamura M, Meguro T, Kobayashi T, Dazai M, Sakata Y, Komatsu Y.

HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of IRIS/Bev in patients with metastatic colorectal cancer: Analysis of first line treatment.

[一般口演] 第59回日本癌治療学会学術集会. 横浜. Oct 21-23, 2021

Hatanaka K, Yuki S, Ito K, Yamamura T, Yagisawa M, Sawada K, Ishiguro A, Muto O, Nakatsumi H, Ueda A, Tateyama M, Sogabe S, Matsumoto R, Sakata Y, Komatsu Y.

HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of IRIS/Bev in patients with metastatic colorectal cancer: Analysis of second line treatment.

[一般口演] 第59回日本癌治療学会学術集会. 横浜. Oct 21-23, 2021

Saito K, Ito K, Yuki S, Kawamoto Y, Yagisawa M, Sawada K, Sato A, Tsuji Y, Ando T, Nakano S, Wakabayashi T, Kotaka M, Takahashi Y, Sakata Y, Komatsu Y.

HGCSG1901: A Retrospective Cohort Study Evaluating the Safety and Efficacy of IRIS/Bev as second line treatment for metastatic colorectal cancer patients after anti-EGFR antibody.

[口演] 第59回日本癌治療学会学術集会. 横浜. Oct 21-23, 2021

Muto O, Kawamoto Y, Yuki S, Nakamura M, Sawada K, Sogabe S, Shindo Y, Ishiguro A, Sato A, Tsuji Y, Dazai M, Okuda H, Harada K, Ito Y, Sakata Y, Komatsu Y.

Final analysis of HGCSG1603: a phase 2 trial of ramucirumab plus irinotecan combination therapy as second-line treatment for patients with advanced gastric cancer.

[口演] 第59回日本癌治療学会学術集会. 横浜. Oct 21-23, 2021

Ishiguro A, Nakamura M, Dazai M, Kawamoto Y, Yuki S, Sogabe S, Hosokawa A, Sawada K, Osamu M, Izawa N, Mitsuhashi Y, Ando T, Kikuchi Y, Komatsu Y.

The safety and efficacy of edoxaban for the cancer-associated asympromatic venous thromboembolism in Japanese gastrointestinal cancer patients receiving chemotherapy. (ExCAVE study)

[口演] 第59回日本癌治療学会学術集会. 横浜. Oct 21-23, 2021

Yamamura T, Harada K, Sogabe S, Sawada K, Yagisawa M, Nakano S, Dazai M, Tateyama M, Ito K, Saito R, Kawamoto Y, Yuki S, Sakamoto N, Sakata Y, Komatsu Y.

HGCSG2101: The real-world experience of nanoliposomal irinotecan plus fluorouracil/leucovorin in Japanese patients with advanced pancreatic adenocarcinoma: a multi-center, retrospective cohort study.

[ポスター] 第59回日本癌治療学会学術集会. 横浜. Oct 21-23, 2021

中村路夫, 石黒敦, 太宰昌佳, 川本泰之, 結城敏志, 曽我部進, 細川歩, 澤田憲太郎, 菊池穏香, 山中竹春, 小松嘉人

The efficacy of edoxaban for the cancer-associated asymptomatic venous thromboembolism in Japanese gastrointestinal cancer patients receiving chemotherapy: subgroup analysis of ExCAVE study.

[一般口演] 第4回日本腫瘍循環器学会学術集会. WEB. Oct 12-14, 2021

Sawada K, Kawamoto Y, Yuki S, Nakamura M, Muto O, Sogabe S, Shindo Y, Ishiguro A, Sato A, Tsuji Y, Dazai M, Okuda H, Sasaki T, Harada K, Nakano S, Nakatsumi H, Sekiguchi M, Sakata Y, Sakamoto N, Komatsu Y.

HGCSG1603: A phase 2 trial of ramucirumab plus irinotecan as second-line treatment for advanced gastric cancer.

[Mini-Oral Session] 第18回日本臨床腫瘍学会学術集会. WEB. Feb 18-21, 2021

2020年

村中徹人, 小松嘉人, 結城敏志, 中野真太郎, 澤田憲太郎, 川本泰之, 中積宏之, 原田一顕, 宮城島拓人,畑中一映, 太宰昌佳, 植田亮, 笹木祐介, 辻靖, 西本尚樹, 坂田優, 坂本直哉 S-1・カペシタビンを含む標準治療に不応・不耐の胃癌に対するbolus 5-FU/l-LV療法の多施設共同第II相試験：前治療別の解析一般口演第16回日本消化管学会学術集会. 姫路. Feb 07-08, 2020

Ito K, Yuki S, Nakatsumi H, Ando T, Dazai M, Hatanaka K, Miyagishima T, Hisai H, Ishiguro A, Ueda A, Sasaki T, Shindo Y, Sakamoto N, Sakata Y, Komatsu Y HGCSG1902: Multicenter, prospective, observational study for cases with dysgeusia in gastrointestinal cancer patients caused by chemotherapy. ポスター [Trial in progress] 第57回日本癌治療学会学術集会. 京都. Oct 22-24, 2020

Harada K, Nakatsumi H, Kawamoto Y, Yuki S, Ishiguro A, Tateyama M, Miyagishima T, Nakamura M, Dazai M, Okuda H, Hatanaka K, Amano T, Komatsu Y HGCSG1301: A phase II trial comparing Hange-shashin-to vs placebo to prevent diarrhea in patients with mCRC treated with IRIS/Bev as second-line therapy: updated analysis of anti-tumor efficacy. ポスター第57回日本癌治療学会学術集会. 京都. Oct 22-24, 2020

2009年

第95回日本消化器病学会総会 2009．5．札幌．治癒切除不能進行/再発結腸直腸癌におけるベバシズマブ（BV）の有用性を検討するレトロスペクティブ調査（HGCSG0801）結城敏志，小松嘉人，浅香正博：ワークショップ

治癒切除不能進行/再発結腸直腸癌におけるベバシツマブ（BV）の有用性を検討するレトロスペクティブ調査（HGCSG0801）--一次治療例の検討宮城島拓人，結城敏志，岩永一郎，久須美貴哉，太宰昌佳，中村路夫，加藤総介，小林秋人，西研，梶浦新也，細川歩，月岡雄治，赤倉伸亮，渡邊豊，畑中一映，片桐雅樹，加藤貴司，目黒高志，浅香正博，小松嘉人：一般口演

治癒切除不能進行/再発結腸直腸癌におけるベバシズマブ（BV）の有用性を検討するレトロスペクティブ調査（HGCSG0801）--2次治療例の検討工藤峰生，結城敏志，曽我部進，久須美貴哉，細川正夫，畑中一映，成瀬宏仁，山内純，加藤寛士，高木智史，宮下憲暢，梶浦新也，細川歩，渡邊豊，佐々木尚英，宮城島拓人，加藤貴司，中村路夫，浅賀正博，小松嘉人：一般口演

治癒切除不能進行/再発結腸直腸癌におけるベバシズマブ（BV）の有用性を検討するレトロスペクティブ調査（HGCSG0801）--3次治療以降の検討加藤貴司，結城敏史，川本泰之，上畠寧子，赤倉伸亮，渡邊豊，畑中一映，成瀬宏仁，宮城島拓人，目黒高志，竹内啓，武藤修一，上林実，渡辺雅男，久須美貴哉，高野眞寿，工藤峰生，舘山美樹，浅香正博，小松嘉人：一般口演

第47回日本癌治療学会総会 2009．9．横浜大腸癌化学療法世界との乖離は埋められたか？切除不能大腸癌二次治療例に対するFOLFIRIとIRISとの第III相臨床試験（FIRIS study）辻晃仁，仁科智裕，山口研成，瀧内比呂也，江崎泰斗，徳永伸也，桑野博行，小松嘉人，安井久晃，島田安博，朴成和，渡邊昌彦，兵頭一之介，森田智視，杉原健一：シンポジウム

Bevacizumabの有用性を検討するレトロスペクティブ調査（HGCSG0801）年齢別の解析小松嘉人，結城敏志，曽我部進，大西俊介，宮城島拓人，畑中一映，成瀬宏仁，加藤貴司，目黒高志，鎌田豪，上林実，中村路夫，細川歩，久須美貴哉，浅香正博：一般口演

Bevacizumabの有用性を検討するレトロスペクティブ調査（HGCSG0801）FOLFIRI＋BVの解析竹内啓，結城敏志，中積宏之，天野虎次，林秀幸，畑中一映，加藤貴司，目黒高志，上畠寧子，武藤修一，久須美貴哉，月岡雄治，渡辺豊，浅香正博，小松嘉人：一般口演

JDDW 2009 2009．10．京都．治癒切除不能進行/再発結腸直腸癌におけるベバシズマブ（BV）の有用性を検討するレトロスペクティブ調査（HGCSG0801）結城敏志，小松嘉人，浅香正博：パネルディスカッション

第47回日本癌治療学会総会 2009．10．横浜 Bevacizumabの有用性を検討するレトロスペクティブ調査（HGCSG0801）1次治療例の検討細川歩，結城敏志，曽我部進，梶浦新也，腰山達美，西研，小田寿，宮城島拓人，久須美貴哉，月岡雄治，高野眞寿，工藤峰生，渡辺豊，浅香正博，小松嘉人竹内啓，結城敏志，：一般口演

Bevacizumabの有用性を検討するレトロスペクティブ調査（HGCSG0801）--FOLFIRI＋BVの解析中積宏之，天野虎次，林秀幸，畑中一映，加藤貴司，目黒高志，上畠寧子，武藤修一，久須美貴哉，月岡雄治，渡辺豊，浅香正博，小松嘉人：一般口演

Bevacizumabの有用性を検討するレトロスペクティブ調査（HGCSG0801）―3次治療以降の検討竹内啓，結城敏志，中積宏之，天野虎次，林秀幸，畑中一映，加藤貴司，目黒高志，上畠寧子，武藤修一，久須美貴哉，月岡雄治，渡辺豊，浅香正博，小松嘉人：一般口演

Bevacizumabの有用性を検討するレトロスペクティブ調査（HGCSG0801）結城敏志，小松嘉人，岩永一郎，久須美貴哉，成瀬宏仁，畑中一映，梶浦新也，細川歩，加藤貴司，目黒高志，太宰昌佳，宮城島拓人，中村路夫，渡辺豊，浅香正博：一般口演

第8回日本臨床腫瘍学会学術集会 2010．3．東京．切除不能結腸直腸癌に対するBevacizumabの安全性および有用性を検討するレトロスペクティブ調査（HGCSG0801）曽我部進，結城敏志，岩永一郎，成瀬宏仁，宮城島拓人，中村路夫，工藤峰生，細川歩，久須美貴哉，堀田彰一，渡辺豊，武藤修一，月岡雄治，浅香正博，小松嘉人

切除不能進行結腸直腸癌に対するセツキシマブ使用症例のレトロスペクティブ調査（HGCSG0901）結城敏志，岩永一郎，辻靖，棟方正樹，細川歩，畑中一映，渡辺豊，久須美貴哉，月岡雄治，宮城島拓人，高野眞寿，古川滋，加藤貴司，浅香正博，小松嘉人：一般口演

切除不能進行結腸直腸癌に対するセツキシマブ使用症例のレトロスペクティブ調査（HGCSG0901）--KRAS status別の解析古川孝広，結城敏志，曽我部進，奥田博介，佐藤康史，竹内啓，梶浦新也，伊東重豪，斎藤聡，棟方正樹，舘山美樹，林秀幸，松永明宏，坂田優，小松嘉人：一般口演

切除不能進行結腸直腸癌に対するセツキシマブ使用症例のレトロスペクティブ調査（HGCSG0901）--Cetuximab単剤使用例の解析小川浩平，結城敏志，佐々木尚英，古川孝広，辻靖，小川浩司，棟方正樹，細川正夫，太田智之，川畑修平，宮下憲暢，渡辺豊，小林隆司，坂田優，小松嘉人：ポスター

結城敏志, 小松嘉人, 川本泰之, 曽我部進, 園田範和, 高木智史, 工藤峰生, 目黒高志, 古川滋, 上林実, 若浜理, 宮下憲暢, 竹内啓, 浅香正博, 坂田優切除不能/術後再発結腸・直腸癌に対するCPT-11＋S-1併用療法 (IRIS療法) の第II相臨床試験 (HGCSG0302)：最終解析一般口演第7回日本臨床腫瘍学会総会. 名古屋, Mar 20-21, 2009

畑中一映, 結城敏志, 岩永一郎, 久須美貴哉, 渡邊豊, 加藤貴司, 細川歩, 宮城島拓人, 月岡雄治, 中村路夫, 武藤修一, 工藤峰生, 宮下憲暢, 浅香正博, 小松嘉人治癒切除不能進行/再発結腸直腸癌におけるベバシズマブ (BV) の有用性を検討するレトロスペクティブ調査 (HGCSG0801) 一般口演第7回日本臨床腫瘍学会総会. 名古屋, Mar 20-21, 2009

加藤貴司, 結城敏志, 川本泰之, 上畠寧子, 寺井潔, 渡邊豊, 畑中一映, 成瀬宏仁, 宮城島拓人, 目黒高志, 竹内啓, 羽田政平, 上林実, 渡辺雅男, 久須美貴哉, 高野眞寿, 工藤峰生, 舘山美樹, 浅香正博, 小松嘉人治癒切除不能進行/再発結腸直腸癌におけるベバシズマブ (BV) の有用性を検討するレトロスペクティブ調査 (HGCSG0801) - 3次治療以降の検討一般口演第95回日本消化器病学会総会. 札幌, May 7-9, 2009

工藤峰生, 結城敏志, 曽我部進, 久須美貴哉, 細川正夫, 畑中一映, 成瀬宏仁, 山内純, 加藤寛士, 高木智史, 宮下憲暢, 梶浦新也, 細川歩, 渡邊豊, 佐々木尚英, 宮城島拓人, 加藤貴司, 中村路夫, 浅香正博, 小松嘉人治癒切除不能進行/再発結腸直腸癌におけるベバシズマブ (BV) の有用性を検討するレトロスペクティブ調査 (HGCSG0801) - 2次治療例の検討一般口演第95回日本消化器病学会総会. 札幌, May 7-9, 2009

宮城島拓人, 結城敏志, 岩永一郎, 久須美貴哉, 太宰昌佳, 中村路夫, 加藤総介, 小林秋人, 西研, 梶浦新也, 細川歩, 月岡雄治, 赤倉伸亮, 渡邊豊, 畑中一映, 片桐雅樹, 加藤貴司, 目黒高志, 浅香正博, 小松嘉人治癒切除不能進行/再発結腸直腸癌におけるベバシズマブ (BV) の有用性を検討するレトロスペクティブ調査 (HGCSG0801) - 1次治療例の検討一般口演第95回日本消化器病学会総会. 札幌, May 7-9, 2009

結城敏志, 小松嘉人, 浅香正博治癒切除不能進行/再発結腸直腸癌におけるベバシズマブ (BV) の有用性を検討するレトロスペクティブ調査 (HGCSG0801) ワークショップ第95回日本消化器病学会総会. 札幌, May 7-9, 2009

結城敏志, 小松嘉人, 浅香正博治癒切除不能進行/再発結腸直腸癌におけるベバシズマブ (BV) の有用性を検討するレトロスペクティブ調査 (HGCSG0801) パネルディスカッション JDDW 2009. 京都, Oct 14-17, 2009

中村路夫, 小松嘉人, 結城敏志, 畑中一映, 宮城島拓人, 工藤峰生, 西研, 目黒高志, 舘山美樹, 棟方正樹, 坂田優, 浅香正博進行・再発大腸癌に対するIrinotecan＋TS-1＋Bevacizumab (IRIS/Bev) 併用臨床第II相試験一般口演第47回日本癌治療学会総会. 横浜, Oct 22-24, 2009

竹内啓, 結城敏志, 中積宏之, 天野虎次, 林秀幸, 畑中一映, 加藤貴司, 目黒高志, 上畠寧子, 武藤修一, 久須美貴哉, 月岡雄治, 渡邊豊, 浅香正博, 小松嘉人 Bevacizumabの有用性を検討するレトロスペクティブ調査 (HGCSG0801) - FOLFIRI＋BVの解析一般口演第47回日本癌治療学会総会. 横浜, Oct 22-24, 2009

中村路夫, 結城敏志, 岩永一郎, 西川秀司, 山内純, 畑中一映, 宮下憲暢, 藤永明, 加藤寛士, 國枝保幸, 久須美貴哉, 月岡雄治, 渡邊豊, 浅香正博, 小松嘉人 Bevacizumabの有用性を検討するレトロスペクティブ調査 (HGCSG0801) - FOLFOX＋BVの解析一般口演第47回日本癌治療学会総会. 横浜, Oct 22-24, 2009

小松嘉人, 結城敏志, 曽我部進, 大西俊介, 宮城島拓人, 畑中一映, 成瀬宏仁, 加藤貴司, 目黒高志, 鎌田豪, 上林実, 中村路夫, 細川歩, 久須美貴哉, 浅香正博 Bevacizumabの有用性を検討するレトロスペクティブ調査 (HGCSG0801) - 年齢別の解析一般口演第47回日本癌治療学会総会. 横浜, Oct 22-24, 2009

中積宏之, 結城敏志, 加藤貴司, 目黒高志, 畑中一映, 山本義也, 高野眞寿, 工藤峰生, 小野雄司, 高木智史, 久須美貴哉, 月岡雄治, 渡邊豊, 浅香正博, 小松嘉人 Bevacizumabの有用性を検討するレトロスペクティブ調査 (HGCSG0801) - 3次治療以降の検討一般口演第47回日本癌治療学会総会. 横浜, Oct 22-24, 2009

加藤総介, 結城敏志, 佐々木尚英, 中園綾乃, 畑中一映, 片桐雅樹, 上畠寧子, 武藤修一, 宮下憲暢, 内田多久實, 久須美貴哉, 月岡雄治, 渡邊豊, 浅香正博, 小松嘉人 Bevacizumabの有用性を検討するレトロスペクティブ調査 (HGCSG0801) - 2次治療例の検討一般口演第47回日本癌治療学会総会. 横浜, Oct 22-24, 2009

細川歩, 結城敏志, 曽我部進, 梶浦新也, 腰山達美, 西研, 小田寿, 宮城島拓人, 久須美貴哉, 月岡雄治, 高野眞寿, 工藤峰生, 渡邊豊, 浅香正博, 小松嘉人 Bevacizumabの有用性を検討するレトロスペクティブ調査 (HGCSG0801) - 1次治療例の検討一般口演第47回日本癌治療学会総会. 横浜, Oct 22-24, 2009

結城敏志, 小松嘉人, 岩永一郎, 久須美貴哉, 成瀬宏仁, 畑中一映, 梶浦新也, 細川歩, 加藤貴司, 目黒高志, 太宰昌佳, 宮城島拓人, 中村路夫, 渡邊豊, 浅香正博 Bevacizumabの有用性を検討するレトロスペクティブ調査 (HGCSG0801) 一般口演第47回日本癌治療学会総会. 横浜, Oct 22-24, 2009

2008年

結城敏志、小松嘉人、福島拓、岩永一郎、町田望、小笹真理子、工藤峰生、加藤貴司、宮城島拓人、西研、熊谷直子、坂田優、浅香正博手術不能/術後再発大腸癌に対するmFOLFOX6療法のFeasibility Study：最終解析－HGCSG0501 第6回日本臨床腫瘍学会総会(福岡)

結城敏志, 小松嘉人, 福島拓, 岩永一郎, 町田望, 小笹真理子, 工藤峰生, 加藤貴司, 宮城島拓人, 西研, 熊谷直子, 坂田優, 浅香正博手術不能/術後再発大腸癌に対するmFOLFOX6療法のFeasibility Study：最終解析 - HGCSG0501 ポスター第6回日本臨床腫瘍学会総会. 福岡, Mar 20-21, 2008

結城敏志, 小松嘉人, 浅香正博手術不能または術後再発大腸癌に対するCPT-11＋S-1併用療法 (IRIS療法) の第II相臨床試験 (HGCSG0302)：最終解析結果シンポジウム JDDW 2008. 東京, Oct 1-4, 2008

中村路夫, 小松嘉人, 川本泰之, 上畠寧子, 結城敏志, 西研, 若浜理, 上林実, 熊谷直子, 浅香正博, 坂田優手術不能/術後再発大腸癌に対するmFOLFOX6療法のFeasibility Study：最終解析 - HGCSG0501 一般口演第46回日本癌治療学会総会. 名古屋, Oct 30-Nov 1, 2008

結城敏志, 小松嘉人, 曽我部進, 岩永一郎, 中村路夫, 畑中一映, 加藤貴司, 舘山美樹, 工藤峰生, 宮城島拓人, 浅香正博, 坂田優手術不能または術後再発大腸癌に対するCPT-11＋S-1併用療法 (IRIS療法) の第II相臨床試験 (HGCSG0302)：最終解析結果一般口演第46回日本癌治療学会総会. 名古屋, Oct 30-Nov 1, 2008

2007年

結城敏志、小松嘉人、岩永一郎、小笹真理子、工藤峰生、目黒高志、宮城島拓人、西研、浅香正博、坂田優手術不能または術後再発大腸癌に対するmFOLFOX6(l-OHP＋l-LV＋5-FU)療法のFeasibility Study＜HGCSG0501＞-Hokkaido Gastrointestinal Cancer Study Group- 第45回日本癌治療学会総会(京都)

福島拓、小松嘉人、結城敏志、町田望、舘山美樹、高木智史、若浜理、渡辺雅男、浅香正博、坂田優手術不能または術後再発大腸癌に対するCPT-11＋S-1併用療法(IRIS療法)の第Ⅱ相臨床試験(HGCSG0302) 第45回日本癌治療学会総会(京都)

結城敏志、小松嘉人、浅香正博切除不能進行結腸直腸癌に対するIrinotecan＋S-1併用療法(IRIS療法)のEvidence構築への道 –HGCSG0302：Phase II studyの結果を中心に第93回日本消化器病学会総会(青森)

結城敏志, 小松嘉人, 浅香正博切除不能進行結腸直腸癌に対するIrinotecan＋S-1併用療法 (IRIS療法) のEvidence構築への道 - HGCSG0302：Phase II studyの結果を中心にワークショップ第93回日本消化器病学会総会. 青森, Apr 19-21, 2007

結城敏志, 小松嘉人, 岩永一郎, 小笹真理子, 工藤峰生, 目黒高志, 宮城島拓人, 西研, 浅香正博, 坂田優手術不能または術後再発大腸癌に対するmFOLFOX6 (l-OHP＋l-LV＋5-FU) 療法のFeasibility Study (HGCSG0501) - Hokkaido Gastrointestinal Cancer Study Group - 一般口演第45回日本癌治療学会総会. 京都, Oct 24-26, 2007

福島拓, 小松嘉人, 結城敏志, 町田望, 舘山美樹, 高木智史, 若浜理, 渡辺雅男, 浅香正博, 坂田優手術不能または術後再発大腸癌に対するCPT-11＋S-1併用療法 (IRIS療法) の第II相臨床試験 (HGCSG0302) ワークショップ第45回日本癌治療学会総会. 京都, Oct 24-26, 2007

2006年

小松嘉人、結城敏志、加藤総介、加藤寛士、加藤貴司、上林実、宮下憲暢、西研、若浜理、古川滋、鈴木岳、舘山美樹、秋田弘俊、浅香正博、坂田優手術不能・術後再発大腸癌に対するCPT-11＋S-1併用療法(IRIS)の臨床第II相試験-HGCSG0302- 第4回日本臨床腫瘍学会総会(大阪)

小松嘉人、結城敏志、工藤峰生、西研、鈴木岳、目黒高志、若浜理、舘山美樹、宮城島拓人、宮下憲暢、浅香正博、坂田優. Hokkaido Gastrointestinal Cancer Study Group (HGCSG)における活動報告. 第78回日本胃癌学会総会(大阪)

結城敏志、小松嘉人、布施望、岩永一郎、加藤貴司、宮城島拓人、舘山美樹、工藤峰生、目黒高志、小笹茂、渡辺雅男、武田宏司、浅香正博、坂田優. 切除不能進行食道癌に対する化学療法-HGCSG0305 切除不能進行食道癌に対するDocetaxel+CDDP+5-FU(TPF)併用療法の第I/II相臨床試験を中心に-. DDW-Japan 2006(札幌)

結城敏志、小松嘉人、布施望、小笹真理子、加藤総介、加藤寛士、目黒高志、渡辺雅男、内田多久實、小笹茂、若浜理、古川滋、岸本篤人、鈴木岳、小西茂、舘山美樹、加藤元嗣、武田宏司、浅香正博、坂田優手術不能または術後再発大腸癌に対するCPT-11＋S-1併用療法(IRIS)の臨床第II相試験＜HGCSG0302＞-Hokkaido Gastrointestinal Cancer Study Group- 第92回日本消化器病学会総会(小倉)

宮城島拓人、小松嘉人、結城敏志、布施望、天野虎次、中村路夫、国枝保幸、葭内史朗、西川秀司、大原行雄、常松泉、西研、小田寿、加藤貴司、佐々木清貴、川村直之、工藤峰生、浅香正博、坂田優手術不能進行結腸直腸癌に対するmFOLFOX6療法のFeasibility Study＜HGCSG0501＞-Hokkaido Gastrointestinal Cancer Study Group- 第92回日本消化器病学会総会(小倉)

小松嘉人, 結城敏志, 工藤峰生, 西研, 目黒高志, 若浜理, 舘山美樹, 宮城島拓人, 宮下憲暢, 浅香正博, 坂田優 Hokkaido Gastrointestinal Cancer Study Group (HGCSG) における活動報告ワークショップ第78回日本胃癌学会総会. 大阪, Mar 10-11, 2006

結城敏志, 小松嘉人, 布施望, 町田望, 小笹真理子, 天野虎次, 上畠寧子, 中村路夫, 常松泉, 宮城島拓人, 目黒高志, 工藤峰生, 秋田弘俊, 浅香正博, 坂田優手術不能進行結腸・直腸癌に対するmFOLFOX6 (l-OHP＋l-LV＋5-FU) 療法のFeasibility Study - HGCSG0501 - ポスターディスカッション第4回日本臨床腫瘍学会総会. 大阪, Mar 17-18, 2006

小松嘉人, 結城敏志, 加藤総介, 加藤寛士, 加藤貴司, 上林実, 宮下憲暢, 西研, 若浜理, 古川滋, 鈴木岳, 舘山美樹, 秋田弘俊, 浅香正博, 坂田優手術不能・術後再発大腸癌に対するCPT-11＋S-1併用療法 (IRIS) の臨床第II相試験 - HGCSG0302 - ポスターディスカッション第4回日本臨床腫瘍学会総会. 大阪, Mar 17-18, 2006

結城敏志, 小松嘉人, 布施望, 小笹真理子, 加藤総介, 加藤寛士, 目黒高志, 渡辺雅男, 内田多久實, 小笹茂, 若浜理, 古川滋, 岸本篤人, 鈴木岳, 小西茂, 舘山美樹, 加藤元嗣, 武田宏司, 浅香正博, 坂田優手術不能または術後再発大腸癌に対するCPT-11＋S-1併用療法 (IRIS) の臨床第II相試験 (HGCSG0302) - Hokkaido Gastrointestinal Cancer Study Group - 一般口演第92回日本消化器病学会総会. 北九州, Apr 20-22, 2006

宮城島拓人, 小松嘉人, 結城敏志, 布施望, 天野虎次, 上畠寧子, 中村路夫, 國枝保幸, 葭内史朗, 西川秀司, 大原行雄, 常松泉, 西研, 小田寿, 加藤貴司, 佐々木清貴, 川村直之, 工藤峰生, 浅香正博, 坂田優手術不能進行結腸・直腸癌に対するmFOLFOX6 (l-OHP＋l-LV＋5-FU) 療法のFeasibility Study (HGCSG0501) - Hokkaido Gastrointestinal Cancer Study Group - 一般口演第92回日本消化器病学会総会. 北九州, Apr 20-22, 2006

小松嘉人, 結城敏志, 浅香正博大腸癌遠隔臓器転移に対する化学療法：HGCSGのCPT-11＋S-1 (IRIS) とmFOLFOX6の臨床試験を通じて一般口演第92回日本消化器病学会総会. 北九州, Apr 20-22, 2006

結城敏志, 小松嘉人, 布施望, 岩永一郎, 加藤貴司, 宮城島拓人, 舘山美樹, 工藤峰生, 目黒高志, 小笹茂, 渡辺雅男, 武田宏司, 浅香正博, 坂田優切除不能進行食道癌に対する化学療法 - HGCSG0305：切除不能進行食道癌に対するDocetaxel＋CDDP＋5-FU (TPF) 併用療法の第I/II相臨床試験を中心に - ポスター DDW-Japan 2006. 札幌, Oct 10-14, 2006

2005年

小松嘉人、町田望、結城敏志、天野虎次、竹内啓、小笹真理子、布施望、武居正明、宮下憲暢、加藤貴司、古川滋、川村直之、秋田弘俊、浅香正博手術不能再発進行結腸・直腸癌に対するCPT-11＋S-1併用療法のPhase II臨床試験第3回日本臨床腫瘍学会総会(横浜)

小松嘉人 FOLFOXの治療経験副作用対策を含めて第43回日本癌治療学会総会サテライトシンポジウム(名古屋)

小笹真理子、小松嘉人、町田望、結城敏志、布施望、宮下憲暢、武居正明、天野虎次、竹内啓、加藤貴司、宮城島拓人、舘山美樹、工藤峰生、目黒高志、大泉弘子、渡辺雅男、武田宏司、加藤元嗣、秋田弘俊、浅香正博既治療食道癌に対するDocetaxel＋Cisplatin＋5-FU併用療法（TPF療法）の第I/II相臨床試験〜HGCSG0305-(2)〜第91回日本消化器病学会総会(東京)

河上洋、小松嘉人、上林実、小西康平、小笹真理子、町田望、結城敏志、宮下憲暢、信田亜一郎、浅香正博切除不能進行および術後再発膵癌に対するGemcitabine＋S-1併用療法（GEM＋S-1療法）のパイロット試験第91回日本消化器病学会総会(東京)

小松嘉人胃癌の化学療法-現状と将来展望- 第77回日本胃癌学会総会ランチョンセミナー(横浜)

町田望、小松嘉人、結城敏志、小笹真理子、布施望、武居正明、宮下憲暢、古川滋、加藤貴司、宮城島拓人、舘山美樹、工藤峰生、渡辺雅男、加藤元嗣、浅香正博手術不能・術後再発食道癌に対するTPF療法のprospective study 第59回日本食道学会総会(東京)

町田望, 小松嘉人, 結城敏志, 天野虎次, 竹内啓, 小笹真理子, 布施望, 武居正明, 宮下憲暢, 加藤貴司, 古川滋, 川村直之, 秋田弘俊, 浅香正博 CPT-11を含むレジメンに耐性の進行結腸・直腸癌に対するmodified FOLFOX療法のfeasibility study ポスターディスカッション第3回日本臨床腫瘍学会総会. 横浜, Mar 4-5, 2005

結城敏志, 小松嘉人, 町田望, 小笹真理子, 武居正明, 天野虎次, 竹内啓, 秋田弘俊, 加藤貴司, 古川滋, 工藤峰生, 浅香正博手術不能進行・術後再発食道癌に対するTPF療法の第I/II相臨床試験 (HGCSG) - 第2報 - ポスターディスカッション第3回日本臨床腫瘍学会総会. 横浜, Mar 4-5, 2005

小松嘉人, 町田望, 結城敏志, 天野虎次, 竹内啓, 小笹真理子, 布施望, 武居正明, 宮下憲暢, 加藤貴司, 古川滋, 川村直之, 秋田弘俊, 浅香正博手術不能再発進行結腸・直腸癌に対するCPT-11＋S-1併用療法のPhase II臨床試験ポスターディスカッション第3回日本臨床腫瘍学会総会. 横浜, Mar 4-5, 2005

河上洋, 小松嘉人, 上林実, 小西康平, 小笹真理子, 町田望, 結城敏志, 宮下憲暢, 信田亜一郎, 浅香正博切除不能進行および術後再発膵癌に対するGemcitabine＋S-1併用療法 (GEM＋S-1療法) のパイロット試験ポスター第91回日本消化器病学会総会. 東京, Apr 14-16, 2005

小笹真理子, 小松嘉人, 町田望, 結城敏志, 布施望, 宮下憲暢, 武居正明, 天野虎次, 竹内啓, 加藤貴司, 宮城島拓人, 舘山美樹, 工藤峰生, 目黒高志, 大泉弘子, 渡辺雅男, 武田宏司, 加藤元嗣, 秋田弘俊, 浅香正博既治療食道癌に対するDocetaxel＋Cisplatin＋5-FU併用療法 (TPF療法) の第I/II相臨床試験〜 HGCSG0305-2 〜一般口演第91回日本消化器病学会総会. 東京, Apr 14-16, 2005

町田望, 小松嘉人, 結城敏志, 小笹真理子, 布施望, 武居正明, 宮下憲暢, 古川滋, 加藤貴司, 宮城島拓人, 舘山美樹, 工藤峰生, 渡辺雅男, 加藤元嗣, 秋田弘俊, 浅香正博手術不能・術後再発食道癌に対するTPF療法のprospective study 要望演題第59回日本食道学会総会. 東京, Jun 30-Jul 1, 2005

天野虎次, 小松嘉人, 結城敏志, 竹内啓, 小笹真理子, 町田望, 布施望, 宮下憲暢, 清水勇一, 加藤元嗣, 武田宏司, 秋田弘俊, 浅香正博 Docetaxel＋CDDP＋5-FU併用化学療法 (TPF療法) が有効であった進行食道癌の2例ポスター第43回日本癌治療学会総会. 名古屋, Oct 25-27, 2005

結城敏志, 小松嘉人, 小笹真理子, 加藤寛士, 加藤総介, 中村路夫, 加藤貴司, 宮城島拓人, 舘山美樹, 工藤峰生, 目黒高志, 小笹茂, 渡辺雅男, 秋田弘俊, 浅香正博, 坂田優手術不能進行・術後再発進行食道癌に対するDocetaxel＋CDDP＋5-FU併用療法 (TPF療法) の臨床第I/II相試験～ HGCSG0305 ～一般口演第43回日本癌治療学会総会. 名古屋, Oct 25-27, 2005

2004年

結城敏志、小松嘉人、布施望、武居正明、古川滋、浅香正博、宮城島拓人、工藤峰生、加藤貴司、目黒高志、渡辺雅男、内田多久實、坂田優. 切除不能・術後再発進行結腸直腸癌に対するCPT-11＋l-LV＋5-FU併用療法の臨床第Ⅱ相試験(第３報)〜Hokkaido Gastrointestinal Cancer Study Group（HGCSG）〜. 第2回日本臨床腫瘍学会(東京)

小松嘉人、結城敏志、浅香正博進行再発大腸癌に対する治療戦略―新規抗癌剤併用療法CPT-11＋TS-1の第 II 相臨床試験（第一報）を中心に第42回日本癌治療学会総会(京都)

結城敏志、小松嘉人、浅香正博手術不能進行・術後再発食道癌に対するDocetaxel＋Cisplatin＋5-FU併用療法(TPF療法)の臨床第 I/II 相試験〜Hokkaido Gastrointestinal Cancer Study Group(HGCSG)〜第42回日本癌治療学会総会(京都)

町田望、小松嘉人、結城敏志、小笹真理子、布施望、武居正明、宮下憲暢、加藤貴司、宮城島拓人、舘山美樹、工藤峰生、目黒高志、大泉弘子、渡辺雅男、加藤元嗣、秋田弘俊、浅香正博既治療食道癌に対するDocetaxel＋Cisplatin＋5-FU併用療法(TPF療法)の臨床第 I/II 相試験〜Hokkaido Gastrointestinal Cancer Study Group (HGCSG)〜第42回日本癌治療学会総会(京都)

小松嘉人切除不能・術後再発進行胃癌に対するCPT-11＋S-1併用療法の臨床第I/II相試験 DIF meeting 2004(東京)

結城敏志, 小松嘉人, 布施望, 武居正明, 古川滋, 浅香正博, 宮城島拓人, 工藤峰生, 加藤貴司, 目黒高志, 渡辺雅男, 内田多久實, 坂田優. 切除不能・術後再発進行結腸直腸癌に対するCPT-11＋l-LV＋5-FU併用療法の臨床第II相試験 (第３報) 〜 Hokkaido Gastrointestinal Cancer Study Group (HGCSG) 〜ポスターディスカッション第2回日本臨床腫瘍学会総会. 東京, Mar 12-13, 2004

町田望, 小松嘉人, 結城敏志, 小笹真理子, 布施望, 武居正明, 宮下憲暢, 加藤貴司, 宮城島拓人, 舘山美樹, 工藤峰生, 目黒高志, 大泉弘子, 渡辺雅男, 加藤元嗣, 秋田弘俊, 浅香正博既治療食道癌に対するDocetaxel＋Cisplatin＋5-FU併用療法 (TPF療法) の臨床第I/II相試験～ Hokkaido Gastrointestinal Cancer Study Group (HGCSG) ～ポスター第42回日本癌治療学会総会. 京都, Oct 27-29, 2004

結城敏志, 小松嘉人, 浅香正博手術不能進行・術後再発食道癌に対するDocetaxel＋Cisplatin＋5-FU併用療法 (TPF療法) の臨床第I/II相試験～ Hokkaido Gastrointestinal Cancer Study Group (HGCSG) ～ワークショップ第42回日本癌治療学会総会. 京都, Oct 27-29, 2004

小松嘉人, 結城敏志, 浅香正博進行再発大腸癌に対する治療戦略 - 新規抗癌剤併用療法CPT-11＋TS-1の第II相臨床試験 (第一報) を中心にシンポジウム第42回日本癌治療学会総会. 京都, Oct 27-29, 2004

CONTACT

お問い合わせ

011-706-5657

お問い合わせフォーム